[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$feKi4CKU5k0xGNRALpK4pdfr_SCC2zQ_ySBimBjg65KA":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":76,"rows":83},"Barbara Ann Karmanos Cancer Institute",[4],156,false,20,2,7976,16,35,[14,17,19,22,25,28,30,32],{"name":15,"count":16},"Lung Cancer",15,{"name":18,"count":16},"Breast Cancer",{"name":20,"count":21},"Prostate Cancer",13,{"name":23,"count":24},"Multiple Myeloma and Plasma Cell Neoplasm",12,{"name":26,"count":27},"Leukemia",10,{"name":29,"count":27},"Lymphoma",{"name":31,"count":27},"Unspecified Adult Solid Tumor, Protocol Specific",{"name":33,"count":34},"Myelodysplastic Syndromes",8,[36,41,46,51,56,61,66,71],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT04479267","Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma","2025-06-19","Prednisone",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT06107738","Iberdomide and Daratumumab As Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma","2025-12-31","Iberdomide",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT06420167","DapagliFLOzin in Renal AL Amyloidosis (FLORAL)","2026-04","Dapagliflozin",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT06576115","Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer","2027-07","Nab paclitaxel",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT07098299","Metformin Combined With Chemotherapy and\u002For Immunotherapy in Solid Malignancies","2027-07-07","Metformin",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT03147885","Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma","2027-12","Selinexor",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT05556473","F-Tryptophan PET\u002FCT in Human Cancers","2027-12-31","1-(2-[18F]FLUOROETHYL)-L-Tryptophan",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT07130903","Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer","2028-04-17","Fruquintinib",[77,78,79,80,81,82],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[84,146,215,269,299,320,342,360,383,401,435,453,471,489,591,612,636,715,812,862,900,971,1006,1047,1093,1123,1153,1205,1238,1283,1312,1338,1366,1388,1424,1452,1474,1511,1542,1573,1595,1617,1639,1661,1691,1713,1735,1753,1771,1789,1807,1825,1843,1867,1885,1903,1921,1939,1957,1983,2009,2027,2045,2063,2085,2113,2136,2159,2186,2204,2222,2240,2263,2281,2299,2324,2350,2375,2393,2411,2434,2452,2470,2488,2510,2528,2550,2568,2605,2633,2651,2669,2691,2717,2735,2759,2781,2805,2823,2841,2864,2882,2904,2928,2946,2964,2986,3012,3030,3051,3073,3103,3121,3151,3169,3191,3209,3272,3329,3377,3505,3550,3594,3624,3670,3700,3744,3770,3796,3823,3850,3868,3886,3904,3927,3950,3971,3989,4007,4025],{"intervention":85,"totalTrials":86,"cells":87},"Gemcitabine",4,{"EARLY_PHASE1":88,"PHASE1":91,"PHASE2":93,"PHASE3":140,"PHASE4":142,"NA":144},{"trials":89,"activeCount":90},[],0,{"trials":92,"activeCount":90},[],{"trials":94,"activeCount":139,"soonestReadout":54},[95,108,116,127],{"nctId":96,"briefTitle":97,"status":98,"phases":99,"primaryCompletion":100,"completion":101,"start":102,"enrollment":103,"conditions":104,"interventions":106},"NCT00248560","Gemcitabine and Docetaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer","COMPLETED",[79],"2009-12","2012-06","2005-01",36,[105],"Head and Neck Cancer",[107,85],"docetaxel",{"nctId":52,"briefTitle":53,"status":109,"phases":110,"primaryCompletion":54,"completion":54,"start":111,"enrollment":112,"conditions":113,"interventions":115},"RECRUITING",[79],"2025-02-28",30,[114],"Metastatic Pancreatic Adenocarcinoma",[55,85],{"nctId":117,"briefTitle":118,"status":98,"phases":119,"primaryCompletion":120,"completion":121,"start":122,"enrollment":123,"conditions":124,"interventions":125},"NCT00244933","Gemcitabine Hydrochloride and Genistein in Treating Women With Stage IV Breast Cancer",[79],"2008-11","2009-10","2004-02",19,[18],[126],"gemcitabine",{"nctId":128,"briefTitle":129,"status":98,"phases":130,"primaryCompletion":131,"completion":131,"start":132,"enrollment":133,"conditions":134,"interventions":136},"NCT00618826","A Study of Biweekly Gemcitabine, Paclitaxel, and Avastin in Patients With Metastatic Breast Cancer",[79],"2014-02","2006-11",14,[135],"Metastatic Breast Cancer",[137,85,138],"Paclitaxel","Avastin",1,{"trials":141,"activeCount":90},[],{"trials":143,"activeCount":90},[],{"trials":145,"activeCount":90},[],{"intervention":40,"totalTrials":86,"cells":147},{"EARLY_PHASE1":148,"PHASE1":150,"PHASE2":163,"PHASE3":209,"PHASE4":211,"NA":213},{"trials":149,"activeCount":90},[],{"trials":151,"activeCount":90},[152],{"nctId":153,"briefTitle":154,"status":98,"phases":155,"primaryCompletion":156,"completion":157,"start":158,"enrollment":159,"conditions":160,"interventions":162},"NCT00890617","Cryotherapy in Treating Patients With Primary Stage I Non-Small Cell Lung Cancer or Lung Metastasis",[78],"2019-07-27","2021-05","2009-03",9,[15,161],"Metastatic Cancer",[40],{"trials":164,"activeCount":139,"soonestReadout":39},[165,180,191],{"nctId":166,"briefTitle":167,"status":98,"phases":168,"primaryCompletion":169,"completion":169,"start":170,"enrollment":171,"conditions":172,"interventions":177},"NCT01468532","Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer",[78,79],"2017-07-20","2011-10",18,[173,174,175,176],"Adenocarcinoma of the Prostate","Hormone-resistant Prostate Cancer","Recurrent Prostate Cancer","Stage IV Prostate Cancer",[107,178,179],"pasireotide","prednisone",{"nctId":181,"briefTitle":182,"status":98,"phases":183,"primaryCompletion":184,"completion":184,"start":185,"enrollment":186,"conditions":187,"interventions":188},"NCT01051570","Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel",[79],"2013-09","2010-02",26,[20],[189,190,179],"carboplatin","RAD 001",{"nctId":37,"briefTitle":38,"status":192,"phases":193,"primaryCompletion":39,"completion":194,"start":195,"enrollment":34,"conditions":196,"interventions":202},"ACTIVE_NOT_RECRUITING",[79],"2026-07-19","2020-08-21",[197,198,199,200,201],"Diffuse Large B-Cell Lymphoma","High Grade B-Cell Lymphoma w\u002FMYC & BCL2 or BCL6 Rearrangements","High Grade B-Cell Lymphoma w\u002FMYC, BCL2 & BCL6 Rearrangements","Double Expressor Lymphoma","High-grade B-cell Lymphoma",[40,203,204,205,206,207,208],"Prednisolone","Methylprednisolone","Rituximab","Polatuzumab Vedotin","Cyclophosphamide","Doxorubicin Hydrochloride",{"trials":210,"activeCount":90},[],{"trials":212,"activeCount":90},[],{"trials":214,"activeCount":90},[],{"intervention":216,"totalTrials":217,"cells":218},"rituximab",3,{"EARLY_PHASE1":219,"PHASE1":221,"PHASE2":223,"PHASE3":263,"PHASE4":265,"NA":267},{"trials":220,"activeCount":90},[],{"trials":222,"activeCount":90},[],{"trials":224,"activeCount":139,"soonestReadout":39},[225,244,259],{"nctId":226,"briefTitle":227,"status":98,"phases":228,"primaryCompletion":229,"completion":229,"start":230,"enrollment":231,"conditions":232,"interventions":235},"NCT00691015","Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant",[79],"2014-04","2008-05",48,[233,26,29,23,33,234],"Chronic Myeloproliferative Disorders","Myelodysplastic\u002FMyeloproliferative Neoplasms",[216,236,237,238,239,240,241,242,243],"busulfan","carmustine","cyclophosphamide","cytarabine","etoposide","fludarabine phosphate","melphalan","anti-thymocyte globulin IV",{"nctId":245,"briefTitle":246,"status":247,"phases":248,"primaryCompletion":249,"completion":250,"start":251,"enrollment":86,"conditions":252,"interventions":255},"NCT01116232","Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation","TERMINATED",[79],"2013-05","2013-06","2010-08",[233,253,26,29,254,23,33,234],"Graft Versus Host Disease","Lymphoproliferative Disorder",[256,216,257,258],"anti-thymocyte globulin","sirolimus","tacrolimus",{"nctId":37,"briefTitle":38,"status":192,"phases":260,"primaryCompletion":39,"completion":194,"start":195,"enrollment":34,"conditions":261,"interventions":262},[79],[197,198,199,200,201],[40,203,204,205,206,207,208],{"trials":264,"activeCount":90},[],{"trials":266,"activeCount":90},[],{"trials":268,"activeCount":90},[],{"intervention":270,"totalTrials":9,"cells":271},"doxorubicin hydrochloride",{"EARLY_PHASE1":272,"PHASE1":274,"PHASE2":276,"PHASE3":293,"PHASE4":295,"NA":297},{"trials":273,"activeCount":90},[],{"trials":275,"activeCount":90},[],{"trials":277,"activeCount":139,"soonestReadout":39},[278,289],{"nctId":279,"briefTitle":280,"status":247,"phases":281,"primaryCompletion":282,"completion":283,"start":284,"enrollment":34,"conditions":285,"interventions":286},"NCT01147016","Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery",[79],"2017-07-01","2017-07-26","2010-07",[18],[287,238,270,288],"HER2Bi-armed activated T cells","paclitaxel",{"nctId":37,"briefTitle":38,"status":192,"phases":290,"primaryCompletion":39,"completion":194,"start":195,"enrollment":34,"conditions":291,"interventions":292},[79],[197,198,199,200,201],[40,203,204,205,206,207,208],{"trials":294,"activeCount":90},[],{"trials":296,"activeCount":90},[],{"trials":298,"activeCount":90},[],{"intervention":50,"totalTrials":139,"cells":300},{"EARLY_PHASE1":301,"PHASE1":303,"PHASE2":305,"PHASE3":314,"PHASE4":316,"NA":318},{"trials":302,"activeCount":90},[],{"trials":304,"activeCount":90},[],{"trials":306,"activeCount":139,"soonestReadout":49},[307],{"nctId":47,"briefTitle":48,"status":109,"phases":308,"primaryCompletion":49,"completion":309,"start":310,"enrollment":8,"conditions":311,"interventions":313},[79],"2027-04","2024-07-11",[312],"Renal AL Amyloidosis",[50],{"trials":315,"activeCount":90},[],{"trials":317,"activeCount":90},[],{"trials":319,"activeCount":90},[],{"intervention":75,"totalTrials":139,"cells":321},{"EARLY_PHASE1":322,"PHASE1":324,"PHASE2":326,"PHASE3":336,"PHASE4":338,"NA":340},{"trials":323,"activeCount":90},[],{"trials":325,"activeCount":90},[],{"trials":327,"activeCount":139,"soonestReadout":74},[328],{"nctId":72,"briefTitle":73,"status":109,"phases":329,"primaryCompletion":74,"completion":330,"start":331,"enrollment":332,"conditions":333,"interventions":335},[79],"2030-04-17","2025-09-10",102,[334],"Metastatic Colorectal Adenocarcinoma",[75],{"trials":337,"activeCount":90},[],{"trials":339,"activeCount":90},[],{"trials":341,"activeCount":90},[],{"intervention":55,"totalTrials":139,"cells":343},{"EARLY_PHASE1":344,"PHASE1":346,"PHASE2":348,"PHASE3":354,"PHASE4":356,"NA":358},{"trials":345,"activeCount":90},[],{"trials":347,"activeCount":90},[],{"trials":349,"activeCount":139,"soonestReadout":54},[350],{"nctId":52,"briefTitle":53,"status":109,"phases":351,"primaryCompletion":54,"completion":54,"start":111,"enrollment":112,"conditions":352,"interventions":353},[79],[114],[55,85],{"trials":355,"activeCount":90},[],{"trials":357,"activeCount":90},[],{"trials":359,"activeCount":90},[],{"intervention":45,"totalTrials":139,"cells":361},{"EARLY_PHASE1":362,"PHASE1":364,"PHASE2":366,"PHASE3":377,"PHASE4":379,"NA":381},{"trials":363,"activeCount":90},[],{"trials":365,"activeCount":90},[],{"trials":367,"activeCount":139,"soonestReadout":44},[368],{"nctId":42,"briefTitle":43,"status":109,"phases":369,"primaryCompletion":44,"completion":370,"start":371,"enrollment":372,"conditions":373,"interventions":375},[79],"2026-12-31","2023-12-21",60,[374],"Multiple Myeloma",[45,376],"Daratumumab\u002FrHuPH20 Co-formulation",{"trials":378,"activeCount":90},[],{"trials":380,"activeCount":90},[],{"trials":382,"activeCount":90},[],{"intervention":376,"totalTrials":139,"cells":384},{"EARLY_PHASE1":385,"PHASE1":387,"PHASE2":389,"PHASE3":395,"PHASE4":397,"NA":399},{"trials":386,"activeCount":90},[],{"trials":388,"activeCount":90},[],{"trials":390,"activeCount":139,"soonestReadout":44},[391],{"nctId":42,"briefTitle":43,"status":109,"phases":392,"primaryCompletion":44,"completion":370,"start":371,"enrollment":372,"conditions":393,"interventions":394},[79],[374],[45,376],{"trials":396,"activeCount":90},[],{"trials":398,"activeCount":90},[],{"trials":400,"activeCount":90},[],{"intervention":65,"totalTrials":139,"cells":402},{"EARLY_PHASE1":403,"PHASE1":405,"PHASE2":407,"PHASE3":429,"PHASE4":431,"NA":433},{"trials":404,"activeCount":90},[],{"trials":406,"activeCount":90},[],{"trials":408,"activeCount":139,"soonestReadout":64},[409],{"nctId":62,"briefTitle":63,"status":192,"phases":410,"primaryCompletion":64,"completion":64,"start":411,"enrollment":412,"conditions":413,"interventions":428},[78,79],"2017-06-20",43,[197,414,415,416,417,418,419,420,421,422,423,424,425,426,427],"Recurrent B-Cell Non-Hodgkin Lymphoma","Recurrent Extranodal Marginal Zone Lymphoma","Recurrent Follicular Lymphoma","Recurrent Indolent Adult Non-Hodgkin Lymphoma","Recurrent Mantle Cell Lymphoma","Recurrent Marginal Zone Lymphoma","Recurrent Waldenstrom Macroglobulinemia","Refractory B-Cell Non-Hodgkin Lymphoma","Refractory Extranodal Marginal Zone Lymphoma","Refractory Follicular Lymphoma","Refractory Mantle Cell Lymphoma","Stage III Non-Hodgkin Lymphoma","Stage IV Non-Hodgkin Lymphoma","Transformed Recurrent Non-Hodgkin Lymphoma",[65],{"trials":430,"activeCount":90},[],{"trials":432,"activeCount":90},[],{"trials":434,"activeCount":90},[],{"intervention":203,"totalTrials":139,"cells":436},{"EARLY_PHASE1":437,"PHASE1":439,"PHASE2":441,"PHASE3":447,"PHASE4":449,"NA":451},{"trials":438,"activeCount":90},[],{"trials":440,"activeCount":90},[],{"trials":442,"activeCount":139,"soonestReadout":39},[443],{"nctId":37,"briefTitle":38,"status":192,"phases":444,"primaryCompletion":39,"completion":194,"start":195,"enrollment":34,"conditions":445,"interventions":446},[79],[197,198,199,200,201],[40,203,204,205,206,207,208],{"trials":448,"activeCount":90},[],{"trials":450,"activeCount":90},[],{"trials":452,"activeCount":90},[],{"intervention":204,"totalTrials":139,"cells":454},{"EARLY_PHASE1":455,"PHASE1":457,"PHASE2":459,"PHASE3":465,"PHASE4":467,"NA":469},{"trials":456,"activeCount":90},[],{"trials":458,"activeCount":90},[],{"trials":460,"activeCount":139,"soonestReadout":39},[461],{"nctId":37,"briefTitle":38,"status":192,"phases":462,"primaryCompletion":39,"completion":194,"start":195,"enrollment":34,"conditions":463,"interventions":464},[79],[197,198,199,200,201],[40,203,204,205,206,207,208],{"trials":466,"activeCount":90},[],{"trials":468,"activeCount":90},[],{"trials":470,"activeCount":90},[],{"intervention":206,"totalTrials":139,"cells":472},{"EARLY_PHASE1":473,"PHASE1":475,"PHASE2":477,"PHASE3":483,"PHASE4":485,"NA":487},{"trials":474,"activeCount":90},[],{"trials":476,"activeCount":90},[],{"trials":478,"activeCount":139,"soonestReadout":39},[479],{"nctId":37,"briefTitle":38,"status":192,"phases":480,"primaryCompletion":39,"completion":194,"start":195,"enrollment":34,"conditions":481,"interventions":482},[79],[197,198,199,200,201],[40,203,204,205,206,207,208],{"trials":484,"activeCount":90},[],{"trials":486,"activeCount":90},[],{"trials":488,"activeCount":90},[],{"intervention":238,"totalTrials":159,"cells":490},{"EARLY_PHASE1":491,"PHASE1":493,"PHASE2":495,"PHASE3":570,"PHASE4":572,"NA":574},{"trials":492,"activeCount":90},[],{"trials":494,"activeCount":90},[],{"trials":496,"activeCount":139,"soonestReadout":39},[497,501,505,519,534,548,557,566],{"nctId":279,"briefTitle":280,"status":247,"phases":498,"primaryCompletion":282,"completion":283,"start":284,"enrollment":34,"conditions":499,"interventions":500},[79],[18],[287,238,270,288],{"nctId":226,"briefTitle":227,"status":98,"phases":502,"primaryCompletion":229,"completion":229,"start":230,"enrollment":231,"conditions":503,"interventions":504},[79],[233,26,29,23,33,234],[216,236,237,238,239,240,241,242,243],{"nctId":506,"briefTitle":507,"status":508,"phases":509,"primaryCompletion":510,"completion":510,"start":511,"enrollment":512,"conditions":513,"interventions":515},"NCT03252600","Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis","UNKNOWN",[79],"2023-12-07","2017-08-25",53,[514],"Recurrent Primary Amyloidosis",[207,516,517,518],"Dexamethasone","Elotuzumab","Lenalidomide",{"nctId":520,"briefTitle":521,"status":98,"phases":522,"primaryCompletion":523,"completion":523,"start":524,"conditions":525,"interventions":527},"NCT00014573","Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer",[79],"2004-10","1998-08",[526],"Brain and Central Nervous System Tumors",[528,529,530,531,532,237,533,238,288],"aldesleukin","autologous tumor cell vaccine","filgrastim","sargramostim","therapeutic autologous lymphocytes","cisplatin",{"nctId":535,"briefTitle":536,"status":98,"phases":537,"primaryCompletion":538,"completion":539,"start":540,"enrollment":541,"conditions":542,"interventions":543},"NCT00002552","Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Multiple Myeloma",[79],"2001-09","2003-10","1993-10",40,[29,23],[530,531,237,238,239,240,544,545,546,547],"leucovorin calcium","methotrexate","perfosfamide","therapeutic hydrocortisone",{"nctId":549,"briefTitle":550,"status":98,"phases":551,"primaryCompletion":539,"completion":539,"start":552,"enrollment":553,"conditions":554,"interventions":555},"NCT00002547","Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome",[79],"1987-08",280,[26,33],[236,238,556,239,545],"cyclosporine",{"nctId":558,"briefTitle":559,"status":247,"phases":560,"primaryCompletion":561,"completion":562,"start":563,"enrollment":412,"conditions":564,"interventions":565},"NCT01022138","Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Patients With HER2\u002FNeu-Negative Metastatic Breast Cancer",[79],"2015-11-06","2019-02-19","2010-03-08",[18],[287,207],{"nctId":37,"briefTitle":38,"status":192,"phases":567,"primaryCompletion":39,"completion":194,"start":195,"enrollment":34,"conditions":568,"interventions":569},[79],[197,198,199,200,201],[40,203,204,205,206,207,208],{"trials":571,"activeCount":90},[],{"trials":573,"activeCount":90},[],{"trials":575,"activeCount":90},[576],{"nctId":577,"briefTitle":578,"status":98,"phases":579,"primaryCompletion":580,"completion":581,"start":523,"enrollment":541,"conditions":582,"interventions":588},"NCT00293384","Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant",[82],"2009-06","2012-02",[18,233,583,26,29,23,33,234,584,585,586,587],"Gestational Trophoblastic Tumor","Nausea and Vomiting","Neuroblastoma","Ovarian Cancer","Testicular Germ Cell Tumor",[589,207,516,590],"Aprepitant","Granisetron hydrochloride",{"intervention":60,"totalTrials":139,"cells":592},{"EARLY_PHASE1":593,"PHASE1":595,"PHASE2":604,"PHASE3":606,"PHASE4":608,"NA":610},{"trials":594,"activeCount":90},[],{"trials":596,"activeCount":139,"soonestReadout":59},[597],{"nctId":57,"briefTitle":58,"status":109,"phases":598,"primaryCompletion":59,"completion":599,"start":600,"enrollment":372,"conditions":601,"interventions":603},[78],"2028-07-07","2025-09-18",[602],"Advanced Solid Tumor",[60],{"trials":605,"activeCount":90},[],{"trials":607,"activeCount":90},[],{"trials":609,"activeCount":90},[],{"trials":611,"activeCount":90},[],{"intervention":70,"totalTrials":139,"cells":613},{"EARLY_PHASE1":614,"PHASE1":616,"PHASE2":628,"PHASE3":630,"PHASE4":632,"NA":634},{"trials":615,"activeCount":90},[],{"trials":617,"activeCount":139,"soonestReadout":69},[618],{"nctId":67,"briefTitle":68,"status":109,"phases":619,"primaryCompletion":69,"completion":69,"start":620,"enrollment":621,"conditions":622,"interventions":627},[78],"2022-09-29",24,[623,624,18,625,626],"Intracranial Glioma","Metastatic Brain Tumor","Neuroendocrine Tumors","Rectal Cancer",[70],{"trials":629,"activeCount":90},[],{"trials":631,"activeCount":90},[],{"trials":633,"activeCount":90},[],{"trials":635,"activeCount":90},[],{"intervention":637,"totalTrials":638,"cells":639},"bryostatin 1",7,{"EARLY_PHASE1":640,"PHASE1":642,"PHASE2":663,"PHASE3":709,"PHASE4":711,"NA":713},{"trials":641,"activeCount":90},[],{"trials":643,"activeCount":90},[644,653],{"nctId":645,"briefTitle":646,"status":98,"phases":647,"primaryCompletion":648,"completion":648,"start":649,"enrollment":103,"conditions":650,"interventions":651},"NCT00004144","Bryostatin 1 Plus Gemcitabine in Treating Patients With Advanced Cancer",[78],"2006-12","2000-05",[31],[637,652],"gemcitabine hydrochloride",{"nctId":654,"briefTitle":655,"status":98,"phases":656,"primaryCompletion":657,"completion":657,"start":658,"enrollment":659,"conditions":660,"interventions":661},"NCT00003174","Bryostatin 1 Plus Cladribine in Treating Patients With Relapsed Chronic Lymphocytic Leukemia",[78],"2005-11","1998-05",80,[26],[637,662],"cladribine",{"trials":664,"activeCount":90},[665,675,684,692,701],{"nctId":666,"briefTitle":667,"status":98,"phases":668,"primaryCompletion":669,"completion":670,"start":671,"conditions":672,"interventions":673},"NCT00002908","Bryostatin 1 in Treating Patients With Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia",[79],"2000-02","2001-11","1996-12",[26,29],[637,674],"vincristine sulfate",{"nctId":676,"briefTitle":677,"status":98,"phases":678,"primaryCompletion":679,"completion":680,"start":681,"conditions":682,"interventions":683},"NCT00002907","Bryostatin 1 in Treating Patients With Relapsed Multiple Myeloma",[79],"1999-01","2000-11","1997-01",[23],[637],{"nctId":685,"briefTitle":686,"status":98,"phases":687,"primaryCompletion":688,"completion":689,"start":658,"conditions":690,"interventions":691},"NCT00003171","Bryostatin 1 in Treating Patients With Myelodysplastic Syndrome",[79],"1999-07","2003-06",[26,33],[637],{"nctId":693,"briefTitle":694,"status":98,"phases":695,"primaryCompletion":680,"completion":696,"start":697,"conditions":698,"interventions":700},"NCT00003220","Bryostatin 1 in Treating Patients With Metastatic Colorectal Cancer",[79],"2001-06","1998-02",[699],"Colorectal Cancer",[637],{"nctId":702,"briefTitle":703,"status":98,"phases":704,"primaryCompletion":705,"completion":705,"start":706,"conditions":707,"interventions":708},"NCT00003936","Bryostatin 1 in Treating Patients With Recurrent or Refractory Hodgkin's Disease",[79],"2004-06","1999-06",[29],[637],{"trials":710,"activeCount":90},[],{"trials":712,"activeCount":90},[],{"trials":714,"activeCount":90},[],{"intervention":531,"totalTrials":638,"cells":716},{"EARLY_PHASE1":717,"PHASE1":719,"PHASE2":760,"PHASE3":806,"PHASE4":808,"NA":810},{"trials":718,"activeCount":90},[],{"trials":720,"activeCount":90},[721,733],{"nctId":722,"briefTitle":723,"status":98,"phases":724,"primaryCompletion":725,"completion":726,"start":727,"enrollment":728,"conditions":729,"interventions":730},"NCT00027807","Biological Therapy in Treating Women With Stage IV Breast Cancer",[78],"2010-09","2013-03","2001-10",6,[18],[731,732,532],"Aldesleukin","Sargramostim",{"nctId":734,"briefTitle":735,"status":736,"phases":737,"primaryCompletion":738,"completion":738,"start":739,"enrollment":90,"conditions":740,"interventions":758},"NCT02470559","Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent","WITHDRAWN",[78],"2017-02","2015-06",[741,742,743,744,745,746,747,748,749,750,751,752,753,754,755,756,757],"Malignant Ovarian Clear Cell Tumor","Malignant Ovarian Serous Tumor","Recurrent Fallopian Tube Carcinoma","Recurrent Ovarian Carcinoma","Recurrent Primary Peritoneal Carcinoma","Stage IIIA Fallopian Tube Cancer","Stage IIIA Ovarian Cancer","Stage IIIA Primary Peritoneal Cancer","Stage IIIB Fallopian Tube Cancer","Stage IIIB Ovarian Cancer","Stage IIIB Primary Peritoneal Cancer","Stage IIIC Fallopian Tube Cancer","Stage IIIC Ovarian Cancer","Stage IIIC Primary Peritoneal Cancer","Stage IV Fallopian Tube Cancer","Stage IV Ovarian Cancer","Stage IV Primary Peritoneal Cancer",[731,759,732],"HER2Bi-Armed Activated T Cells",{"trials":761,"activeCount":90},[762,771,780,784,788],{"nctId":763,"briefTitle":764,"status":98,"phases":765,"primaryCompletion":766,"completion":766,"start":767,"enrollment":34,"conditions":768,"interventions":770},"NCT00514215","Cryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung Cancer",[79],"2010-03","2006-01",[769,15,161,31],"Kidney Cancer",[531],{"nctId":772,"briefTitle":773,"status":98,"phases":774,"primaryCompletion":775,"completion":775,"start":776,"enrollment":372,"conditions":777,"interventions":778},"NCT00004024","Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma",[79],"2004-01","1997-06",[526],[528,529,779,531,532],"muromonab-CD3",{"nctId":520,"briefTitle":521,"status":98,"phases":781,"primaryCompletion":523,"completion":523,"start":524,"conditions":782,"interventions":783},[79],[526],[528,529,530,531,532,237,533,238,288],{"nctId":535,"briefTitle":536,"status":98,"phases":785,"primaryCompletion":538,"completion":539,"start":540,"enrollment":541,"conditions":786,"interventions":787},[79],[29,23],[530,531,237,238,239,240,544,545,546,547],{"nctId":789,"briefTitle":790,"status":98,"phases":791,"primaryCompletion":792,"completion":792,"start":793,"enrollment":9,"conditions":794,"interventions":798},"NCT02620865","BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer",[78,79],"2021-06-21","2015-12",[114,795,796,797],"Recurrent Pancreatic Carcinoma","Stage III Pancreatic Cancer","Stage IV Pancreatic Cancer",[731,799,800,801,802,803,804,805,732],"Antibody Therapy","Fluorouracil","Gemcitabine Hydrochloride","Irinotecan Hydrochloride","Leucovorin Calcium","Oxaliplatin","Paclitaxel Albumin-Stabilized Nanoparticle Formulation",{"trials":807,"activeCount":90},[],{"trials":809,"activeCount":90},[],{"trials":811,"activeCount":90},[],{"intervention":532,"totalTrials":728,"cells":813},{"EARLY_PHASE1":814,"PHASE1":816,"PHASE2":830,"PHASE3":856,"PHASE4":858,"NA":860},{"trials":815,"activeCount":90},[],{"trials":817,"activeCount":90},[818,826],{"nctId":819,"briefTitle":820,"status":98,"phases":821,"primaryCompletion":822,"completion":726,"start":823,"enrollment":16,"conditions":824,"interventions":825},"NCT00244946","Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma",[78],"2010-01","2004-03",[29],[532,237,239,240,242],{"nctId":722,"briefTitle":723,"status":98,"phases":827,"primaryCompletion":725,"completion":726,"start":727,"enrollment":728,"conditions":828,"interventions":829},[78],[18],[731,732,532],{"trials":831,"activeCount":90},[832,841,845,849],{"nctId":833,"briefTitle":834,"status":247,"phases":835,"primaryCompletion":726,"completion":726,"start":836,"enrollment":638,"conditions":837,"interventions":838},"NCT00020722","Chemotherapy Followed by Peripheral Stem Cell Transplantation Plus Biological Therapy in Treating Women With Stage IV Breast Cancer",[79],"2007-08",[18],[532,839,840],"Ifosfamide, carboplatin, and etoposide (ICE) regimen","Cyclophosphamide, Thiotepa, Carboplatin",{"nctId":772,"briefTitle":773,"status":98,"phases":842,"primaryCompletion":775,"completion":775,"start":776,"enrollment":372,"conditions":843,"interventions":844},[79],[526],[528,529,779,531,532],{"nctId":520,"briefTitle":521,"status":98,"phases":846,"primaryCompletion":523,"completion":523,"start":524,"conditions":847,"interventions":848},[79],[526],[528,529,530,531,532,237,533,238,288],{"nctId":850,"briefTitle":851,"status":98,"phases":852,"primaryCompletion":775,"completion":775,"start":776,"conditions":853,"interventions":855},"NCT00004022","Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma",[79],[854],"Melanoma (Skin)",[528,529,779,532],{"trials":857,"activeCount":90},[],{"trials":859,"activeCount":90},[],{"trials":861,"activeCount":90},[],{"intervention":528,"totalTrials":728,"cells":863},{"EARLY_PHASE1":864,"PHASE1":866,"PHASE2":876,"PHASE3":894,"PHASE4":896,"NA":898},{"trials":865,"activeCount":90},[],{"trials":867,"activeCount":90},[868,872],{"nctId":722,"briefTitle":723,"status":98,"phases":869,"primaryCompletion":725,"completion":726,"start":727,"enrollment":728,"conditions":870,"interventions":871},[78],[18],[731,732,532],{"nctId":734,"briefTitle":735,"status":736,"phases":873,"primaryCompletion":738,"completion":738,"start":739,"enrollment":90,"conditions":874,"interventions":875},[78],[741,742,743,744,745,746,747,748,749,750,751,752,753,754,755,756,757],[731,759,732],{"trials":877,"activeCount":90},[878,882,886,890],{"nctId":772,"briefTitle":773,"status":98,"phases":879,"primaryCompletion":775,"completion":775,"start":776,"enrollment":372,"conditions":880,"interventions":881},[79],[526],[528,529,779,531,532],{"nctId":520,"briefTitle":521,"status":98,"phases":883,"primaryCompletion":523,"completion":523,"start":524,"conditions":884,"interventions":885},[79],[526],[528,529,530,531,532,237,533,238,288],{"nctId":850,"briefTitle":851,"status":98,"phases":887,"primaryCompletion":775,"completion":775,"start":776,"conditions":888,"interventions":889},[79],[854],[528,529,779,532],{"nctId":789,"briefTitle":790,"status":98,"phases":891,"primaryCompletion":792,"completion":792,"start":793,"enrollment":9,"conditions":892,"interventions":893},[78,79],[114,795,796,797],[731,799,800,801,802,803,804,805,732],{"trials":895,"activeCount":90},[],{"trials":897,"activeCount":90},[],{"trials":899,"activeCount":90},[],{"intervention":533,"totalTrials":901,"cells":902},5,{"EARLY_PHASE1":903,"PHASE1":905,"PHASE2":926,"PHASE3":965,"PHASE4":967,"NA":969},{"trials":904,"activeCount":90},[],{"trials":906,"activeCount":90},[907],{"nctId":908,"briefTitle":909,"status":98,"phases":910,"primaryCompletion":911,"completion":912,"start":913,"enrollment":914,"conditions":915,"interventions":924},"NCT01958372","Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell Lung Cancer",[78],"2017-10-09","2019-11-11","2014-08",11,[916,917,918,919,920,921,922,923],"Adenocarcinoma of the Lung","Adenosquamous Cell Lung Cancer","Bronchoalveolar Cell Lung Cancer","Large Cell Lung Cancer","Recurrent Non-small Cell Lung Cancer","Squamous Cell Lung Cancer","Stage IIIA Non-small Cell Lung Cancer","Stage IIIB Non-small Cell Lung Cancer",[533,240,925],"pemetrexed disodium",{"trials":927,"activeCount":90},[928,938,950,961],{"nctId":929,"briefTitle":930,"status":98,"phases":931,"primaryCompletion":670,"completion":932,"start":933,"enrollment":112,"conditions":934,"interventions":936},"NCT00004003","Combination Chemotherapy in Treating Patients With Stage III or Stage IV Pancreatic Cancer That Cannot Be Removed by Surgery",[79],"2003-08","1999-04",[935],"Pancreatic Cancer",[533,937,652],"fluorouracil",{"nctId":939,"briefTitle":940,"status":98,"phases":941,"primaryCompletion":942,"completion":943,"start":944,"enrollment":728,"conditions":945,"interventions":946},"NCT00248482","Imatinib Mesylate After Irinotecan and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer",[79],"2005-04","2008-01","2002-02",[15],[947,948,949],"Cisplatin","Gleevec™","irinotecan",{"nctId":951,"briefTitle":952,"status":98,"phases":953,"primaryCompletion":954,"completion":955,"start":657,"enrollment":956,"conditions":957,"interventions":958},"NCT00301808","Cisplatin, Pemetrexed Disodium, and Radiation Therapy Followed by Docetaxel in Treating Patients With Stage III Non-Small Cell Lung Cancer",[79],"2012-09","2012-10",29,[15],[947,959,960],"Docetaxel","Pemetrexed disodium",{"nctId":520,"briefTitle":521,"status":98,"phases":962,"primaryCompletion":523,"completion":523,"start":524,"conditions":963,"interventions":964},[79],[526],[528,529,530,531,532,237,533,238,288],{"trials":966,"activeCount":90},[],{"trials":968,"activeCount":90},[],{"trials":970,"activeCount":90},[],{"intervention":288,"totalTrials":86,"cells":972},{"EARLY_PHASE1":973,"PHASE1":975,"PHASE2":977,"PHASE3":1000,"PHASE4":1002,"NA":1004},{"trials":974,"activeCount":90},[],{"trials":976,"activeCount":90},[],{"trials":978,"activeCount":90},[979,988,992,996],{"nctId":980,"briefTitle":981,"status":247,"phases":982,"primaryCompletion":943,"completion":983,"start":984,"enrollment":9,"conditions":985,"interventions":986},"NCT00459121","Vandetanib, Carboplatin, and Paclitaxel in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed by Surgery",[79],"2008-10","2007-07",[15],[189,288,987],"Zactima",{"nctId":279,"briefTitle":280,"status":247,"phases":989,"primaryCompletion":282,"completion":283,"start":284,"enrollment":34,"conditions":990,"interventions":991},[79],[18],[287,238,270,288],{"nctId":520,"briefTitle":521,"status":98,"phases":993,"primaryCompletion":523,"completion":523,"start":524,"conditions":994,"interventions":995},[79],[526],[528,529,530,531,532,237,533,238,288],{"nctId":128,"briefTitle":129,"status":98,"phases":997,"primaryCompletion":131,"completion":131,"start":132,"enrollment":133,"conditions":998,"interventions":999},[79],[135],[137,85,138],{"trials":1001,"activeCount":90},[],{"trials":1003,"activeCount":90},[],{"trials":1005,"activeCount":90},[],{"intervention":287,"totalTrials":86,"cells":1007},{"EARLY_PHASE1":1008,"PHASE1":1010,"PHASE2":1016,"PHASE3":1041,"PHASE4":1043,"NA":1045},{"trials":1009,"activeCount":90},[],{"trials":1011,"activeCount":90},[1012],{"nctId":734,"briefTitle":735,"status":736,"phases":1013,"primaryCompletion":738,"completion":738,"start":739,"enrollment":90,"conditions":1014,"interventions":1015},[78],[741,742,743,744,745,746,747,748,749,750,751,752,753,754,755,756,757],[731,759,732],{"trials":1017,"activeCount":90},[1018,1022,1037],{"nctId":279,"briefTitle":280,"status":247,"phases":1019,"primaryCompletion":282,"completion":283,"start":284,"enrollment":34,"conditions":1020,"interventions":1021},[79],[18],[287,238,270,288],{"nctId":1023,"briefTitle":1024,"status":98,"phases":1025,"primaryCompletion":1026,"completion":1027,"start":1028,"enrollment":16,"conditions":1029,"interventions":1035},"NCT03406858","Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer",[79],"2021-01-20","2022-11-07","2018-06-07",[1030,1031,1032,1033,1034],"Castration Levels of Testosterone","Castration-Resistant Prostate Carcinoma","Prostate Carcinoma Metastatic in the Bone","PSA Progression","Stage IV Prostate Adenocarcinoma AJCC v7",[759,1036],"Pembrolizumab",{"nctId":558,"briefTitle":559,"status":247,"phases":1038,"primaryCompletion":561,"completion":562,"start":563,"enrollment":412,"conditions":1039,"interventions":1040},[79],[18],[287,207],{"trials":1042,"activeCount":90},[],{"trials":1044,"activeCount":90},[],{"trials":1046,"activeCount":90},[],{"intervention":242,"totalTrials":86,"cells":1048},{"EARLY_PHASE1":1049,"PHASE1":1051,"PHASE2":1067,"PHASE3":1087,"PHASE4":1089,"NA":1091},{"trials":1050,"activeCount":90},[],{"trials":1052,"activeCount":90},[1053,1057],{"nctId":819,"briefTitle":820,"status":98,"phases":1054,"primaryCompletion":822,"completion":726,"start":823,"enrollment":16,"conditions":1055,"interventions":1056},[78],[29],[532,237,239,240,242],{"nctId":1058,"briefTitle":1059,"status":98,"phases":1060,"primaryCompletion":170,"completion":954,"start":1061,"enrollment":1062,"conditions":1063,"interventions":1065},"NCT00482846","Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma",[78],"2007-06",38,[1064,374],"Mucositis",[1066,242],"Palifermin",{"trials":1068,"activeCount":90},[1069,1083],{"nctId":1070,"briefTitle":1071,"status":98,"phases":1072,"primaryCompletion":1073,"completion":1074,"start":1075,"enrollment":12,"conditions":1076,"interventions":1079},"NCT00520767","Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease",[79],"2010-10","2019-06-06","2007-09",[1077,1078],"Primary Systemic Amyloidosis","Light Chain Deposition Disease",[1080,1081,242,1082],"bortezomib","dexamethasone","microarray analysis",{"nctId":226,"briefTitle":227,"status":98,"phases":1084,"primaryCompletion":229,"completion":229,"start":230,"enrollment":231,"conditions":1085,"interventions":1086},[79],[233,26,29,23,33,234],[216,236,237,238,239,240,241,242,243],{"trials":1088,"activeCount":90},[],{"trials":1090,"activeCount":90},[],{"trials":1092,"activeCount":90},[],{"intervention":237,"totalTrials":86,"cells":1094},{"EARLY_PHASE1":1095,"PHASE1":1097,"PHASE2":1103,"PHASE3":1117,"PHASE4":1119,"NA":1121},{"trials":1096,"activeCount":90},[],{"trials":1098,"activeCount":90},[1099],{"nctId":819,"briefTitle":820,"status":98,"phases":1100,"primaryCompletion":822,"completion":726,"start":823,"enrollment":16,"conditions":1101,"interventions":1102},[78],[29],[532,237,239,240,242],{"trials":1104,"activeCount":90},[1105,1109,1113],{"nctId":226,"briefTitle":227,"status":98,"phases":1106,"primaryCompletion":229,"completion":229,"start":230,"enrollment":231,"conditions":1107,"interventions":1108},[79],[233,26,29,23,33,234],[216,236,237,238,239,240,241,242,243],{"nctId":520,"briefTitle":521,"status":98,"phases":1110,"primaryCompletion":523,"completion":523,"start":524,"conditions":1111,"interventions":1112},[79],[526],[528,529,530,531,532,237,533,238,288],{"nctId":535,"briefTitle":536,"status":98,"phases":1114,"primaryCompletion":538,"completion":539,"start":540,"enrollment":541,"conditions":1115,"interventions":1116},[79],[29,23],[530,531,237,238,239,240,544,545,546,547],{"trials":1118,"activeCount":90},[],{"trials":1120,"activeCount":90},[],{"trials":1122,"activeCount":90},[],{"intervention":240,"totalTrials":86,"cells":1124},{"EARLY_PHASE1":1125,"PHASE1":1127,"PHASE2":1137,"PHASE3":1147,"PHASE4":1149,"NA":1151},{"trials":1126,"activeCount":90},[],{"trials":1128,"activeCount":90},[1129,1133],{"nctId":819,"briefTitle":820,"status":98,"phases":1130,"primaryCompletion":822,"completion":726,"start":823,"enrollment":16,"conditions":1131,"interventions":1132},[78],[29],[532,237,239,240,242],{"nctId":908,"briefTitle":909,"status":98,"phases":1134,"primaryCompletion":911,"completion":912,"start":913,"enrollment":914,"conditions":1135,"interventions":1136},[78],[916,917,918,919,920,921,922,923],[533,240,925],{"trials":1138,"activeCount":90},[1139,1143],{"nctId":226,"briefTitle":227,"status":98,"phases":1140,"primaryCompletion":229,"completion":229,"start":230,"enrollment":231,"conditions":1141,"interventions":1142},[79],[233,26,29,23,33,234],[216,236,237,238,239,240,241,242,243],{"nctId":535,"briefTitle":536,"status":98,"phases":1144,"primaryCompletion":538,"completion":539,"start":540,"enrollment":541,"conditions":1145,"interventions":1146},[79],[29,23],[530,531,237,238,239,240,544,545,546,547],{"trials":1148,"activeCount":90},[],{"trials":1150,"activeCount":90},[],{"trials":1152,"activeCount":90},[],{"intervention":1154,"totalTrials":86,"cells":1155},"Celecoxib",{"EARLY_PHASE1":1156,"PHASE1":1158,"PHASE2":1160,"PHASE3":1199,"PHASE4":1201,"NA":1203},{"trials":1157,"activeCount":90},[],{"trials":1159,"activeCount":90},[],{"trials":1161,"activeCount":90},[1162,1171,1179,1188],{"nctId":1163,"briefTitle":1164,"status":98,"phases":1165,"primaryCompletion":1166,"completion":230,"start":689,"enrollment":1167,"conditions":1168,"interventions":1169},"NCT00068653","Gefitinib and Celecoxib in Treating Patients With Refractory Non-Small Cell Lung Cancer",[79],"2007-10",27,[15],[1154,1170],"ZD1839",{"nctId":1172,"briefTitle":1173,"status":98,"phases":1174,"primaryCompletion":1175,"completion":1176,"start":727,"enrollment":621,"conditions":1177,"interventions":1178},"NCT00030420","Celecoxib and Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer",[79],"2004-05","2008-02",[15],[1154,959],{"nctId":1180,"briefTitle":1181,"status":98,"phases":1182,"primaryCompletion":1183,"completion":1184,"start":727,"enrollment":1185,"conditions":1186,"interventions":1187},"NCT00030407","Celecoxib and Docetaxel in Treating Patients With Non-Small Cell Lung Cancer",[79],"2005-09","2009-04",34,[15],[1154,959],{"nctId":1189,"briefTitle":1190,"status":98,"phases":1191,"primaryCompletion":1192,"completion":836,"start":1193,"conditions":1194,"interventions":1195},"NCT00258232","Celecoxib, Capecitabine, and Irinotecan in Treating Patients With Recurrent or Metastatic Colorectal Cancer",[79],"2007-03","2002-01",[699],[1196,1197,1198],"capecitabine","celecoxib","irinotecan hydrochloride",{"trials":1200,"activeCount":90},[],{"trials":1202,"activeCount":90},[],{"trials":1204,"activeCount":90},[],{"intervention":1196,"totalTrials":217,"cells":1206},{"EARLY_PHASE1":1207,"PHASE1":1209,"PHASE2":1211,"PHASE3":1232,"PHASE4":1234,"NA":1236},{"trials":1208,"activeCount":90},[],{"trials":1210,"activeCount":90},[],{"trials":1212,"activeCount":90},[1213,1220,1228],{"nctId":1214,"briefTitle":1215,"status":98,"phases":1216,"primaryCompletion":1217,"completion":1217,"start":932,"enrollment":112,"conditions":1218,"interventions":1219},"NCT00258284","Capecitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer",[79],"2007-11",[20],[1196,107],{"nctId":1221,"briefTitle":1222,"status":98,"phases":1223,"primaryCompletion":1224,"completion":1224,"start":1225,"enrollment":12,"conditions":1226,"interventions":1227},"NCT00258310","Ph II Long Term\u002FLow Dose Xeloda in Head and Neck Squamous Cell Carcinoma After Surgery, Radiation & or Chemo",[79],"2011-02","2003-12",[105],[1196],{"nctId":1189,"briefTitle":1190,"status":98,"phases":1229,"primaryCompletion":1192,"completion":836,"start":1193,"conditions":1230,"interventions":1231},[79],[699],[1196,1197,1198],{"trials":1233,"activeCount":90},[],{"trials":1235,"activeCount":90},[],{"trials":1237,"activeCount":90},[],{"intervention":1239,"totalTrials":217,"cells":1240},"gene expression analysis",{"EARLY_PHASE1":1241,"PHASE1":1243,"PHASE2":1255,"PHASE3":1277,"PHASE4":1279,"NA":1281},{"trials":1242,"activeCount":90},[],{"trials":1244,"activeCount":90},[1245],{"nctId":1246,"briefTitle":1247,"status":736,"phases":1248,"primaryCompletion":1249,"completion":1249,"start":580,"enrollment":90,"conditions":1250,"interventions":1251},"NCT00960427","Studying Biomarkers in Tumor Tissue and Blood Samples From Patients Undergoing Chemotherapy and Radiation Therapy for Stage II or Stage III Rectal Cancer That Can Be Removed By Surgery",[78],"2010-04",[699],[1252,1253,1239,1254],"systemic chemotherapy","RNA analysis","reverse transcriptase-polymerase chain reaction",{"trials":1256,"activeCount":90},[1257,1267],{"nctId":1258,"briefTitle":1259,"status":247,"phases":1260,"primaryCompletion":1261,"completion":1261,"start":1262,"enrollment":34,"conditions":1263,"interventions":1265},"NCT00942422","Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and\u002For Smoldering Multiple Myeloma",[79],"2012-03","2009-11",[23,1264],"Precancerous Condition",[1239,1266],"protein analysis",{"nctId":1268,"briefTitle":1269,"status":98,"phases":1270,"primaryCompletion":1271,"completion":1271,"start":1272,"enrollment":171,"conditions":1273,"interventions":1274},"NCT01270880","Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy",[79],"2014-07","2011-01",[173,174,175,176],[1275,1276,1253,1254,1239],"Hsp90 inhibitor STA-9090","polymerase chain reaction",{"trials":1278,"activeCount":90},[],{"trials":1280,"activeCount":90},[],{"trials":1282,"activeCount":90},[],{"intervention":544,"totalTrials":217,"cells":1284},{"EARLY_PHASE1":1285,"PHASE1":1287,"PHASE2":1296,"PHASE3":1306,"PHASE4":1308,"NA":1310},{"trials":1286,"activeCount":90},[],{"trials":1288,"activeCount":90},[1289],{"nctId":1290,"briefTitle":1291,"status":98,"phases":1292,"primaryCompletion":836,"completion":836,"start":658,"enrollment":103,"conditions":1293,"interventions":1294},"NCT00003925","Combination Chemotherapy In Treating Patients With Advanced Cancer",[78],[31],[652,544,1295],"tegafur-uracil",{"trials":1297,"activeCount":90},[1298,1302],{"nctId":535,"briefTitle":536,"status":98,"phases":1299,"primaryCompletion":538,"completion":539,"start":540,"enrollment":541,"conditions":1300,"interventions":1301},[79],[29,23],[530,531,237,238,239,240,544,545,546,547],{"nctId":789,"briefTitle":790,"status":98,"phases":1303,"primaryCompletion":792,"completion":792,"start":793,"enrollment":9,"conditions":1304,"interventions":1305},[78,79],[114,795,796,797],[731,799,800,801,802,803,804,805,732],{"trials":1307,"activeCount":90},[],{"trials":1309,"activeCount":90},[],{"trials":1311,"activeCount":90},[],{"intervention":529,"totalTrials":217,"cells":1313},{"EARLY_PHASE1":1314,"PHASE1":1316,"PHASE2":1318,"PHASE3":1332,"PHASE4":1334,"NA":1336},{"trials":1315,"activeCount":90},[],{"trials":1317,"activeCount":90},[],{"trials":1319,"activeCount":90},[1320,1324,1328],{"nctId":772,"briefTitle":773,"status":98,"phases":1321,"primaryCompletion":775,"completion":775,"start":776,"enrollment":372,"conditions":1322,"interventions":1323},[79],[526],[528,529,779,531,532],{"nctId":520,"briefTitle":521,"status":98,"phases":1325,"primaryCompletion":523,"completion":523,"start":524,"conditions":1326,"interventions":1327},[79],[526],[528,529,530,531,532,237,533,238,288],{"nctId":850,"briefTitle":851,"status":98,"phases":1329,"primaryCompletion":775,"completion":775,"start":776,"conditions":1330,"interventions":1331},[79],[854],[528,529,779,532],{"trials":1333,"activeCount":90},[],{"trials":1335,"activeCount":90},[],{"trials":1337,"activeCount":90},[],{"intervention":257,"totalTrials":9,"cells":1339},{"EARLY_PHASE1":1340,"PHASE1":1342,"PHASE2":1344,"PHASE3":1360,"PHASE4":1362,"NA":1364},{"trials":1341,"activeCount":90},[],{"trials":1343,"activeCount":90},[],{"trials":1345,"activeCount":90},[1346,1356],{"nctId":1347,"briefTitle":1348,"status":247,"phases":1349,"primaryCompletion":249,"completion":249,"start":581,"enrollment":139,"conditions":1350,"interventions":1355},"NCT01534143","High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant",[79],[1351,1352,1353,1354],"Refractory Multiple Myeloma","Stage I Multiple Myeloma","Stage II Multiple Myeloma","Stage III Multiple Myeloma",[258,257,256,241,236,1080],{"nctId":245,"briefTitle":246,"status":247,"phases":1357,"primaryCompletion":249,"completion":250,"start":251,"enrollment":86,"conditions":1358,"interventions":1359},[79],[233,253,26,29,254,23,33,234],[256,216,257,258],{"trials":1361,"activeCount":90},[],{"trials":1363,"activeCount":90},[],{"trials":1365,"activeCount":90},[],{"intervention":256,"totalTrials":9,"cells":1367},{"EARLY_PHASE1":1368,"PHASE1":1370,"PHASE2":1372,"PHASE3":1382,"PHASE4":1384,"NA":1386},{"trials":1369,"activeCount":90},[],{"trials":1371,"activeCount":90},[],{"trials":1373,"activeCount":90},[1374,1378],{"nctId":1347,"briefTitle":1348,"status":247,"phases":1375,"primaryCompletion":249,"completion":249,"start":581,"enrollment":139,"conditions":1376,"interventions":1377},[79],[1351,1352,1353,1354],[258,257,256,241,236,1080],{"nctId":245,"briefTitle":246,"status":247,"phases":1379,"primaryCompletion":249,"completion":250,"start":251,"enrollment":86,"conditions":1380,"interventions":1381},[79],[233,253,26,29,254,23,33,234],[256,216,257,258],{"trials":1383,"activeCount":90},[],{"trials":1385,"activeCount":90},[],{"trials":1387,"activeCount":90},[],{"intervention":1389,"totalTrials":9,"cells":1390},"thalidomide",{"EARLY_PHASE1":1391,"PHASE1":1393,"PHASE2":1405,"PHASE3":1418,"PHASE4":1420,"NA":1422},{"trials":1392,"activeCount":90},[],{"trials":1394,"activeCount":90},[1395],{"nctId":1396,"briefTitle":1397,"status":98,"phases":1398,"primaryCompletion":1399,"completion":1399,"start":1400,"enrollment":901,"conditions":1401,"interventions":1402},"NCT00258245","Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia",[78],"2008-04","2005-05",[23],[1403,1080,1081,1389,1404],"arsenic trioxide","Aspirin",{"trials":1406,"activeCount":90},[1407],{"nctId":1408,"briefTitle":1409,"status":98,"phases":1410,"primaryCompletion":1411,"completion":1061,"start":1412,"enrollment":1413,"conditions":1414,"interventions":1416},"NCT00238329","PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma",[79],"2005-12","2001-01",32,[1415,854],"Intraocular Melanoma",[1417,1389],"PEG-interferon alfa-2b",{"trials":1419,"activeCount":90},[],{"trials":1421,"activeCount":90},[],{"trials":1423,"activeCount":90},[],{"intervention":1036,"totalTrials":9,"cells":1425},{"EARLY_PHASE1":1426,"PHASE1":1428,"PHASE2":1430,"PHASE3":1446,"PHASE4":1448,"NA":1450},{"trials":1427,"activeCount":90},[],{"trials":1429,"activeCount":90},[],{"trials":1431,"activeCount":90},[1432,1442],{"nctId":1433,"briefTitle":1434,"status":98,"phases":1435,"primaryCompletion":1436,"completion":1436,"start":1437,"enrollment":1438,"conditions":1439,"interventions":1441},"NCT02359019","MK-3475 as Maintenance Therapy in Extensive Stage SCLC",[79],"2018-10","2015-02",45,[1440],"Extensive Stage Small Cell Lung Carcinoma",[1036],{"nctId":1023,"briefTitle":1024,"status":98,"phases":1443,"primaryCompletion":1026,"completion":1027,"start":1028,"enrollment":16,"conditions":1444,"interventions":1445},[79],[1030,1031,1032,1033,1034],[759,1036],{"trials":1447,"activeCount":90},[],{"trials":1449,"activeCount":90},[],{"trials":1451,"activeCount":90},[],{"intervention":189,"totalTrials":9,"cells":1453},{"EARLY_PHASE1":1454,"PHASE1":1456,"PHASE2":1458,"PHASE3":1468,"PHASE4":1470,"NA":1472},{"trials":1455,"activeCount":90},[],{"trials":1457,"activeCount":90},[],{"trials":1459,"activeCount":90},[1460,1464],{"nctId":980,"briefTitle":981,"status":247,"phases":1461,"primaryCompletion":943,"completion":983,"start":984,"enrollment":9,"conditions":1462,"interventions":1463},[79],[15],[189,288,987],{"nctId":181,"briefTitle":182,"status":98,"phases":1465,"primaryCompletion":184,"completion":184,"start":185,"enrollment":186,"conditions":1466,"interventions":1467},[79],[20],[189,190,179],{"trials":1469,"activeCount":90},[],{"trials":1471,"activeCount":90},[],{"trials":1473,"activeCount":90},[],{"intervention":1475,"totalTrials":9,"cells":1476},"Nivolumab",{"EARLY_PHASE1":1477,"PHASE1":1479,"PHASE2":1481,"PHASE3":1505,"PHASE4":1507,"NA":1509},{"trials":1478,"activeCount":90},[],{"trials":1480,"activeCount":90},[],{"trials":1482,"activeCount":90},[1483,1494],{"nctId":1484,"briefTitle":1485,"status":247,"phases":1486,"primaryCompletion":1487,"completion":1487,"start":1488,"enrollment":27,"conditions":1489,"interventions":1492},"NCT04159896","ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer",[79],"2022-03-01","2019-11-13",[1030,1031,1490,1032,1491],"Metastatic Prostate Carcinoma","Stage IVB Prostate Cancer AJCC v8",[1493,1475],"Pan-VEGFR\u002FTIE2 Tyrosine Kinase Inhibitor CEP-11981",{"nctId":1495,"briefTitle":1496,"status":98,"phases":1497,"primaryCompletion":1498,"completion":1498,"start":1499,"enrollment":8,"conditions":1500,"interventions":1504},"NCT03421652","Nivolumab and RT in Treating Patients With Localized\u002FLocally Advanced Urothelial Bladder Cancer Ineligible for Chemo",[79],"2023-03-23","2018-04-24",[1501,1502,1503],"Stage II Bladder Urothelial Carcinoma AJCC v6 and v7","Stage III Bladder Urothelial Carcinoma AJCC v6 and v7","Stage IV Bladder Urothelial Carcinoma AJCC v7",[1475],{"trials":1506,"activeCount":90},[],{"trials":1508,"activeCount":90},[],{"trials":1510,"activeCount":90},[],{"intervention":1512,"totalTrials":9,"cells":1513},"fenretinide",{"EARLY_PHASE1":1514,"PHASE1":1516,"PHASE2":1526,"PHASE3":1536,"PHASE4":1538,"NA":1540},{"trials":1515,"activeCount":90},[],{"trials":1517,"activeCount":90},[1518],{"nctId":1519,"briefTitle":1520,"status":98,"phases":1521,"primaryCompletion":1522,"completion":1522,"start":658,"enrollment":1523,"conditions":1524,"interventions":1525},"NCT00003250","Fenretinide in Treating Patients With Solid Tumors",[78],"2008-12",31,[31],[1512],{"trials":1527,"activeCount":90},[1528],{"nctId":1529,"briefTitle":1530,"status":98,"phases":1531,"primaryCompletion":1532,"completion":1532,"start":1533,"conditions":1534,"interventions":1535},"NCT00011973","Chemotherapy in Treating Patients With Advanced Kidney Cancer",[79],"2005-10","2000-12",[769],[1512],{"trials":1537,"activeCount":90},[],{"trials":1539,"activeCount":90},[],{"trials":1541,"activeCount":90},[],{"intervention":1543,"totalTrials":9,"cells":1544},"pyrazoloacridine",{"EARLY_PHASE1":1545,"PHASE1":1547,"PHASE2":1549,"PHASE3":1567,"PHASE4":1569,"NA":1571},{"trials":1546,"activeCount":90},[],{"trials":1548,"activeCount":90},[],{"trials":1550,"activeCount":90},[1551,1559],{"nctId":1552,"briefTitle":1553,"status":98,"phases":1554,"primaryCompletion":1555,"completion":1412,"start":1556,"enrollment":8,"conditions":1557,"interventions":1558},"NCT00002585","Pyrazoloacridine in Treating Women With Metastatic Breast Cancer",[79],"1999-10","1994-02",[18],[1543],{"nctId":1560,"briefTitle":1561,"status":98,"phases":1562,"primaryCompletion":1563,"completion":1176,"start":1564,"enrollment":8,"conditions":1565,"interventions":1566},"NCT00002656","Pyrazoloacridine in Treating Patients With Advanced Non-small Cell Lung Cancer",[79],"2001-12","1995-10",[15],[1543],{"trials":1568,"activeCount":90},[],{"trials":1570,"activeCount":90},[],{"trials":1572,"activeCount":90},[],{"intervention":937,"totalTrials":9,"cells":1574},{"EARLY_PHASE1":1575,"PHASE1":1577,"PHASE2":1579,"PHASE3":1589,"PHASE4":1591,"NA":1593},{"trials":1576,"activeCount":90},[],{"trials":1578,"activeCount":90},[],{"trials":1580,"activeCount":90},[1581,1585],{"nctId":929,"briefTitle":930,"status":98,"phases":1582,"primaryCompletion":670,"completion":932,"start":933,"enrollment":112,"conditions":1583,"interventions":1584},[79],[935],[533,937,652],{"nctId":789,"briefTitle":790,"status":98,"phases":1586,"primaryCompletion":792,"completion":792,"start":793,"enrollment":9,"conditions":1587,"interventions":1588},[78,79],[114,795,796,797],[731,799,800,801,802,803,804,805,732],{"trials":1590,"activeCount":90},[],{"trials":1592,"activeCount":90},[],{"trials":1594,"activeCount":90},[],{"intervention":1253,"totalTrials":9,"cells":1596},{"EARLY_PHASE1":1597,"PHASE1":1599,"PHASE2":1605,"PHASE3":1611,"PHASE4":1613,"NA":1615},{"trials":1598,"activeCount":90},[],{"trials":1600,"activeCount":90},[1601],{"nctId":1246,"briefTitle":1247,"status":736,"phases":1602,"primaryCompletion":1249,"completion":1249,"start":580,"enrollment":90,"conditions":1603,"interventions":1604},[78],[699],[1252,1253,1239,1254],{"trials":1606,"activeCount":90},[1607],{"nctId":1268,"briefTitle":1269,"status":98,"phases":1608,"primaryCompletion":1271,"completion":1271,"start":1272,"enrollment":171,"conditions":1609,"interventions":1610},[79],[173,174,175,176],[1275,1276,1253,1254,1239],{"trials":1612,"activeCount":90},[],{"trials":1614,"activeCount":90},[],{"trials":1616,"activeCount":90},[],{"intervention":1254,"totalTrials":9,"cells":1618},{"EARLY_PHASE1":1619,"PHASE1":1621,"PHASE2":1627,"PHASE3":1633,"PHASE4":1635,"NA":1637},{"trials":1620,"activeCount":90},[],{"trials":1622,"activeCount":90},[1623],{"nctId":1246,"briefTitle":1247,"status":736,"phases":1624,"primaryCompletion":1249,"completion":1249,"start":580,"enrollment":90,"conditions":1625,"interventions":1626},[78],[699],[1252,1253,1239,1254],{"trials":1628,"activeCount":90},[1629],{"nctId":1268,"briefTitle":1269,"status":98,"phases":1630,"primaryCompletion":1271,"completion":1271,"start":1272,"enrollment":171,"conditions":1631,"interventions":1632},[79],[173,174,175,176],[1275,1276,1253,1254,1239],{"trials":1634,"activeCount":90},[],{"trials":1636,"activeCount":90},[],{"trials":1638,"activeCount":90},[],{"intervention":779,"totalTrials":9,"cells":1640},{"EARLY_PHASE1":1641,"PHASE1":1643,"PHASE2":1645,"PHASE3":1655,"PHASE4":1657,"NA":1659},{"trials":1642,"activeCount":90},[],{"trials":1644,"activeCount":90},[],{"trials":1646,"activeCount":90},[1647,1651],{"nctId":772,"briefTitle":773,"status":98,"phases":1648,"primaryCompletion":775,"completion":775,"start":776,"enrollment":372,"conditions":1649,"interventions":1650},[79],[526],[528,529,779,531,532],{"nctId":850,"briefTitle":851,"status":98,"phases":1652,"primaryCompletion":775,"completion":775,"start":776,"conditions":1653,"interventions":1654},[79],[854],[528,529,779,532],{"trials":1656,"activeCount":90},[],{"trials":1658,"activeCount":90},[],{"trials":1660,"activeCount":90},[],{"intervention":804,"totalTrials":9,"cells":1662},{"EARLY_PHASE1":1663,"PHASE1":1665,"PHASE2":1667,"PHASE3":1685,"PHASE4":1687,"NA":1689},{"trials":1664,"activeCount":90},[],{"trials":1666,"activeCount":90},[],{"trials":1668,"activeCount":90},[1669,1681],{"nctId":1670,"briefTitle":1671,"status":98,"phases":1672,"primaryCompletion":1673,"completion":1674,"start":523,"enrollment":1675,"conditions":1676,"interventions":1679},"NCT00217581","Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction Cancer",[79],"2012-11","2013-01",39,[1677,1678],"Esophageal Cancer","Gastric Cancer",[1680,959,804],"Bevacizumab",{"nctId":789,"briefTitle":790,"status":98,"phases":1682,"primaryCompletion":792,"completion":792,"start":793,"enrollment":9,"conditions":1683,"interventions":1684},[78,79],[114,795,796,797],[731,799,800,801,802,803,804,805,732],{"trials":1686,"activeCount":90},[],{"trials":1688,"activeCount":90},[],{"trials":1690,"activeCount":90},[],{"intervention":545,"totalTrials":9,"cells":1692},{"EARLY_PHASE1":1693,"PHASE1":1695,"PHASE2":1697,"PHASE3":1707,"PHASE4":1709,"NA":1711},{"trials":1694,"activeCount":90},[],{"trials":1696,"activeCount":90},[],{"trials":1698,"activeCount":90},[1699,1703],{"nctId":535,"briefTitle":536,"status":98,"phases":1700,"primaryCompletion":538,"completion":539,"start":540,"enrollment":541,"conditions":1701,"interventions":1702},[79],[29,23],[530,531,237,238,239,240,544,545,546,547],{"nctId":549,"briefTitle":550,"status":98,"phases":1704,"primaryCompletion":539,"completion":539,"start":552,"enrollment":553,"conditions":1705,"interventions":1706},[79],[26,33],[236,238,556,239,545],{"trials":1708,"activeCount":90},[],{"trials":1710,"activeCount":90},[],{"trials":1712,"activeCount":90},[],{"intervention":802,"totalTrials":9,"cells":1714},{"EARLY_PHASE1":1715,"PHASE1":1717,"PHASE2":1719,"PHASE3":1729,"PHASE4":1731,"NA":1733},{"trials":1716,"activeCount":90},[],{"trials":1718,"activeCount":90},[],{"trials":1720,"activeCount":90},[1721,1725],{"nctId":789,"briefTitle":790,"status":98,"phases":1722,"primaryCompletion":792,"completion":792,"start":793,"enrollment":9,"conditions":1723,"interventions":1724},[78,79],[114,795,796,797],[731,799,800,801,802,803,804,805,732],{"nctId":1189,"briefTitle":1190,"status":98,"phases":1726,"primaryCompletion":1192,"completion":836,"start":1193,"conditions":1727,"interventions":1728},[79],[699],[1196,1197,1198],{"trials":1730,"activeCount":90},[],{"trials":1732,"activeCount":90},[],{"trials":1734,"activeCount":90},[],{"intervention":674,"totalTrials":139,"cells":1736},{"EARLY_PHASE1":1737,"PHASE1":1739,"PHASE2":1741,"PHASE3":1747,"PHASE4":1749,"NA":1751},{"trials":1738,"activeCount":90},[],{"trials":1740,"activeCount":90},[],{"trials":1742,"activeCount":90},[1743],{"nctId":666,"briefTitle":667,"status":98,"phases":1744,"primaryCompletion":669,"completion":670,"start":671,"conditions":1745,"interventions":1746},[79],[26,29],[637,674],{"trials":1748,"activeCount":90},[],{"trials":1750,"activeCount":90},[],{"trials":1752,"activeCount":90},[],{"intervention":987,"totalTrials":139,"cells":1754},{"EARLY_PHASE1":1755,"PHASE1":1757,"PHASE2":1759,"PHASE3":1765,"PHASE4":1767,"NA":1769},{"trials":1756,"activeCount":90},[],{"trials":1758,"activeCount":90},[],{"trials":1760,"activeCount":90},[1761],{"nctId":980,"briefTitle":981,"status":247,"phases":1762,"primaryCompletion":943,"completion":983,"start":984,"enrollment":9,"conditions":1763,"interventions":1764},[79],[15],[189,288,987],{"trials":1766,"activeCount":90},[],{"trials":1768,"activeCount":90},[],{"trials":1770,"activeCount":90},[],{"intervention":1493,"totalTrials":139,"cells":1772},{"EARLY_PHASE1":1773,"PHASE1":1775,"PHASE2":1777,"PHASE3":1783,"PHASE4":1785,"NA":1787},{"trials":1774,"activeCount":90},[],{"trials":1776,"activeCount":90},[],{"trials":1778,"activeCount":90},[1779],{"nctId":1484,"briefTitle":1485,"status":247,"phases":1780,"primaryCompletion":1487,"completion":1487,"start":1488,"enrollment":27,"conditions":1781,"interventions":1782},[79],[1030,1031,1490,1032,1491],[1493,1475],{"trials":1784,"activeCount":90},[],{"trials":1786,"activeCount":90},[],{"trials":1788,"activeCount":90},[],{"intervention":243,"totalTrials":139,"cells":1790},{"EARLY_PHASE1":1791,"PHASE1":1793,"PHASE2":1795,"PHASE3":1801,"PHASE4":1803,"NA":1805},{"trials":1792,"activeCount":90},[],{"trials":1794,"activeCount":90},[],{"trials":1796,"activeCount":90},[1797],{"nctId":226,"briefTitle":227,"status":98,"phases":1798,"primaryCompletion":229,"completion":229,"start":230,"enrollment":231,"conditions":1799,"interventions":1800},[79],[233,26,29,23,33,234],[216,236,237,238,239,240,241,242,243],{"trials":1802,"activeCount":90},[],{"trials":1804,"activeCount":90},[],{"trials":1806,"activeCount":90},[],{"intervention":517,"totalTrials":139,"cells":1808},{"EARLY_PHASE1":1809,"PHASE1":1811,"PHASE2":1813,"PHASE3":1819,"PHASE4":1821,"NA":1823},{"trials":1810,"activeCount":90},[],{"trials":1812,"activeCount":90},[],{"trials":1814,"activeCount":90},[1815],{"nctId":506,"briefTitle":507,"status":508,"phases":1816,"primaryCompletion":510,"completion":510,"start":511,"enrollment":512,"conditions":1817,"interventions":1818},[79],[514],[207,516,517,518],{"trials":1820,"activeCount":90},[],{"trials":1822,"activeCount":90},[],{"trials":1824,"activeCount":90},[],{"intervention":518,"totalTrials":139,"cells":1826},{"EARLY_PHASE1":1827,"PHASE1":1829,"PHASE2":1831,"PHASE3":1837,"PHASE4":1839,"NA":1841},{"trials":1828,"activeCount":90},[],{"trials":1830,"activeCount":90},[],{"trials":1832,"activeCount":90},[1833],{"nctId":506,"briefTitle":507,"status":508,"phases":1834,"primaryCompletion":510,"completion":510,"start":511,"enrollment":512,"conditions":1835,"interventions":1836},[79],[514],[207,516,517,518],{"trials":1838,"activeCount":90},[],{"trials":1840,"activeCount":90},[],{"trials":1842,"activeCount":90},[],{"intervention":1844,"totalTrials":139,"cells":1845},"ESK981",{"EARLY_PHASE1":1846,"PHASE1":1848,"PHASE2":1850,"PHASE3":1861,"PHASE4":1863,"NA":1865},{"trials":1847,"activeCount":90},[],{"trials":1849,"activeCount":90},[],{"trials":1851,"activeCount":90},[1852],{"nctId":1853,"briefTitle":1854,"status":98,"phases":1855,"primaryCompletion":1856,"completion":1857,"start":1858,"enrollment":21,"conditions":1859,"interventions":1860},"NCT03456804","ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer",[79],"2023-03-15","2023-05-09","2018-03-08",[1030,1031,1490,1033,1034],[1844],{"trials":1862,"activeCount":90},[],{"trials":1864,"activeCount":90},[],{"trials":1866,"activeCount":90},[],{"intervention":839,"totalTrials":139,"cells":1868},{"EARLY_PHASE1":1869,"PHASE1":1871,"PHASE2":1873,"PHASE3":1879,"PHASE4":1881,"NA":1883},{"trials":1870,"activeCount":90},[],{"trials":1872,"activeCount":90},[],{"trials":1874,"activeCount":90},[1875],{"nctId":833,"briefTitle":834,"status":247,"phases":1876,"primaryCompletion":726,"completion":726,"start":836,"enrollment":638,"conditions":1877,"interventions":1878},[79],[18],[532,839,840],{"trials":1880,"activeCount":90},[],{"trials":1882,"activeCount":90},[],{"trials":1884,"activeCount":90},[],{"intervention":840,"totalTrials":139,"cells":1886},{"EARLY_PHASE1":1887,"PHASE1":1889,"PHASE2":1891,"PHASE3":1897,"PHASE4":1899,"NA":1901},{"trials":1888,"activeCount":90},[],{"trials":1890,"activeCount":90},[],{"trials":1892,"activeCount":90},[1893],{"nctId":833,"briefTitle":834,"status":247,"phases":1894,"primaryCompletion":726,"completion":726,"start":836,"enrollment":638,"conditions":1895,"interventions":1896},[79],[18],[532,839,840],{"trials":1898,"activeCount":90},[],{"trials":1900,"activeCount":90},[],{"trials":1902,"activeCount":90},[],{"intervention":1170,"totalTrials":139,"cells":1904},{"EARLY_PHASE1":1905,"PHASE1":1907,"PHASE2":1909,"PHASE3":1915,"PHASE4":1917,"NA":1919},{"trials":1906,"activeCount":90},[],{"trials":1908,"activeCount":90},[],{"trials":1910,"activeCount":90},[1911],{"nctId":1163,"briefTitle":1164,"status":98,"phases":1912,"primaryCompletion":1166,"completion":230,"start":689,"enrollment":1167,"conditions":1913,"interventions":1914},[79],[15],[1154,1170],{"trials":1916,"activeCount":90},[],{"trials":1918,"activeCount":90},[],{"trials":1920,"activeCount":90},[],{"intervention":948,"totalTrials":139,"cells":1922},{"EARLY_PHASE1":1923,"PHASE1":1925,"PHASE2":1927,"PHASE3":1933,"PHASE4":1935,"NA":1937},{"trials":1924,"activeCount":90},[],{"trials":1926,"activeCount":90},[],{"trials":1928,"activeCount":90},[1929],{"nctId":939,"briefTitle":940,"status":98,"phases":1930,"primaryCompletion":942,"completion":943,"start":944,"enrollment":728,"conditions":1931,"interventions":1932},[79],[15],[947,948,949],{"trials":1934,"activeCount":90},[],{"trials":1936,"activeCount":90},[],{"trials":1938,"activeCount":90},[],{"intervention":949,"totalTrials":139,"cells":1940},{"EARLY_PHASE1":1941,"PHASE1":1943,"PHASE2":1945,"PHASE3":1951,"PHASE4":1953,"NA":1955},{"trials":1942,"activeCount":90},[],{"trials":1944,"activeCount":90},[],{"trials":1946,"activeCount":90},[1947],{"nctId":939,"briefTitle":940,"status":98,"phases":1948,"primaryCompletion":942,"completion":943,"start":944,"enrollment":728,"conditions":1949,"interventions":1950},[79],[15],[947,948,949],{"trials":1952,"activeCount":90},[],{"trials":1954,"activeCount":90},[],{"trials":1956,"activeCount":90},[],{"intervention":1958,"totalTrials":139,"cells":1959},"Nintedanib",{"EARLY_PHASE1":1960,"PHASE1":1962,"PHASE2":1964,"PHASE3":1977,"PHASE4":1979,"NA":1981},{"trials":1961,"activeCount":90},[],{"trials":1963,"activeCount":90},[],{"trials":1965,"activeCount":90},[1966],{"nctId":1967,"briefTitle":1968,"status":98,"phases":1969,"primaryCompletion":1970,"completion":1971,"start":1972,"enrollment":8,"conditions":1973,"interventions":1976},"NCT02568449","Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent",[79],"2017-01-01","2018-06-26","2016-03-15",[1974,1975],"Recurrent Pleural Malignant Mesothelioma","Stage IV Pleural Mesothelioma",[1958],{"trials":1978,"activeCount":90},[],{"trials":1980,"activeCount":90},[],{"trials":1982,"activeCount":90},[],{"intervention":1984,"totalTrials":139,"cells":1985},"A single \"booster\" dose of the Moderna mRNA COVID-19 vaccine",{"EARLY_PHASE1":1986,"PHASE1":1988,"PHASE2":1990,"PHASE3":2003,"PHASE4":2005,"NA":2007},{"trials":1987,"activeCount":90},[],{"trials":1989,"activeCount":90},[],{"trials":1991,"activeCount":90},[1992],{"nctId":1993,"briefTitle":1994,"status":98,"phases":1995,"primaryCompletion":1996,"completion":1996,"start":1997,"enrollment":1998,"conditions":1999,"interventions":2002},"NCT05028374","COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies",[79],"2021-11-02","2021-08-17",119,[374,2000,2001],"AL Amyloidosis","Chronic Lymphocytic Leukemia",[1984],{"trials":2004,"activeCount":90},[],{"trials":2006,"activeCount":90},[],{"trials":2008,"activeCount":90},[],{"intervention":1417,"totalTrials":139,"cells":2010},{"EARLY_PHASE1":2011,"PHASE1":2013,"PHASE2":2015,"PHASE3":2021,"PHASE4":2023,"NA":2025},{"trials":2012,"activeCount":90},[],{"trials":2014,"activeCount":90},[],{"trials":2016,"activeCount":90},[2017],{"nctId":1408,"briefTitle":1409,"status":98,"phases":2018,"primaryCompletion":1411,"completion":1061,"start":1412,"enrollment":1413,"conditions":2019,"interventions":2020},[79],[1415,854],[1417,1389],{"trials":2022,"activeCount":90},[],{"trials":2024,"activeCount":90},[],{"trials":2026,"activeCount":90},[],{"intervention":1266,"totalTrials":139,"cells":2028},{"EARLY_PHASE1":2029,"PHASE1":2031,"PHASE2":2033,"PHASE3":2039,"PHASE4":2041,"NA":2043},{"trials":2030,"activeCount":90},[],{"trials":2032,"activeCount":90},[],{"trials":2034,"activeCount":90},[2035],{"nctId":1258,"briefTitle":1259,"status":247,"phases":2036,"primaryCompletion":1261,"completion":1261,"start":1262,"enrollment":34,"conditions":2037,"interventions":2038},[79],[23,1264],[1239,1266],{"trials":2040,"activeCount":90},[],{"trials":2042,"activeCount":90},[],{"trials":2044,"activeCount":90},[],{"intervention":178,"totalTrials":139,"cells":2046},{"EARLY_PHASE1":2047,"PHASE1":2049,"PHASE2":2051,"PHASE3":2057,"PHASE4":2059,"NA":2061},{"trials":2048,"activeCount":90},[],{"trials":2050,"activeCount":90},[],{"trials":2052,"activeCount":90},[2053],{"nctId":166,"briefTitle":167,"status":98,"phases":2054,"primaryCompletion":169,"completion":169,"start":170,"enrollment":171,"conditions":2055,"interventions":2056},[78,79],[173,174,175,176],[107,178,179],{"trials":2058,"activeCount":90},[],{"trials":2060,"activeCount":90},[],{"trials":2062,"activeCount":90},[],{"intervention":2064,"totalTrials":139,"cells":2065},"oral microencapsulated diindolylmethane",{"EARLY_PHASE1":2066,"PHASE1":2068,"PHASE2":2070,"PHASE3":2079,"PHASE4":2081,"NA":2083},{"trials":2067,"activeCount":90},[],{"trials":2069,"activeCount":90},[],{"trials":2071,"activeCount":90},[2072],{"nctId":2073,"briefTitle":2074,"status":736,"phases":2075,"primaryCompletion":131,"completion":131,"start":101,"enrollment":90,"conditions":2076,"interventions":2078},"NCT01612910","Oral Microencapsulated Diindolylmethane in Treating Patients With Stage II-III Triple Negative, Androgen Receptor Positive Breast Cancer Who Have Undergone Chemotherapy and Surgery",[79],[2077],"Breast Cancer Female",[2064],{"trials":2080,"activeCount":90},[],{"trials":2082,"activeCount":90},[],{"trials":2084,"activeCount":90},[],{"intervention":2086,"totalTrials":139,"cells":2087},"Ibrutinib",{"EARLY_PHASE1":2088,"PHASE1":2090,"PHASE2":2092,"PHASE3":2107,"PHASE4":2109,"NA":2111},{"trials":2089,"activeCount":90},[],{"trials":2091,"activeCount":90},[],{"trials":2093,"activeCount":90},[2094],{"nctId":2095,"briefTitle":2096,"status":98,"phases":2097,"primaryCompletion":2098,"completion":2099,"start":2100,"enrollment":2101,"conditions":2102,"interventions":2106},"NCT02824029","Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma",[79],"2023-05-12","2025-01-08","2016-06",28,[2103,2104,2105],"Classical Hodgkin Lymphoma","Recurrent Hodgkin Lymphoma","Refractory Hodgkin Lymphoma",[2086],{"trials":2108,"activeCount":90},[],{"trials":2110,"activeCount":90},[],{"trials":2112,"activeCount":90},[],{"intervention":2114,"totalTrials":139,"cells":2115},"dolastatin 10",{"EARLY_PHASE1":2116,"PHASE1":2118,"PHASE2":2120,"PHASE3":2130,"PHASE4":2132,"NA":2134},{"trials":2117,"activeCount":90},[],{"trials":2119,"activeCount":90},[],{"trials":2121,"activeCount":90},[2122],{"nctId":2123,"briefTitle":2124,"status":98,"phases":2125,"primaryCompletion":2126,"completion":649,"start":2127,"conditions":2128,"interventions":2129},"NCT00003626","Dolastatin 10 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Hormone Therapy",[79],"1999-12","1998-10",[20],[2114],{"trials":2131,"activeCount":90},[],{"trials":2133,"activeCount":90},[],{"trials":2135,"activeCount":90},[],{"intervention":2137,"totalTrials":139,"cells":2138},"loncastuximab tesirine",{"EARLY_PHASE1":2139,"PHASE1":2141,"PHASE2":2143,"PHASE3":2153,"PHASE4":2155,"NA":2157},{"trials":2140,"activeCount":90},[],{"trials":2142,"activeCount":90},[],{"trials":2144,"activeCount":90},[2145],{"nctId":2146,"briefTitle":2147,"status":736,"phases":2148,"primaryCompletion":44,"completion":44,"start":2149,"enrollment":90,"conditions":2150,"interventions":2152},"NCT05222438","Trial of Loncastuximab Tesirine in High Risk Diffuse Large B-cell Lymphoma Post Transplant",[79],"2022-04-08",[2151],"Relapsed Diffuse Large B-cell Lymphoma",[2137],{"trials":2154,"activeCount":90},[],{"trials":2156,"activeCount":90},[],{"trials":2158,"activeCount":90},[],{"intervention":2160,"totalTrials":139,"cells":2161},"enzalutamide",{"EARLY_PHASE1":2162,"PHASE1":2164,"PHASE2":2166,"PHASE3":2180,"PHASE4":2182,"NA":2184},{"trials":2163,"activeCount":90},[],{"trials":2165,"activeCount":90},[],{"trials":2167,"activeCount":90},[2168],{"nctId":2169,"briefTitle":2170,"status":98,"phases":2171,"primaryCompletion":2172,"completion":2172,"start":2173,"enrollment":2174,"conditions":2175,"interventions":2176},"NCT02058706","LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer",[79],"2021-03-01","2014-05",71,[173,175,176],[2160,2177,2178,2179],"bicalutamide","leuprolide acetate","goserelin acetate",{"trials":2181,"activeCount":90},[],{"trials":2183,"activeCount":90},[],{"trials":2185,"activeCount":90},[],{"intervention":2177,"totalTrials":139,"cells":2187},{"EARLY_PHASE1":2188,"PHASE1":2190,"PHASE2":2192,"PHASE3":2198,"PHASE4":2200,"NA":2202},{"trials":2189,"activeCount":90},[],{"trials":2191,"activeCount":90},[],{"trials":2193,"activeCount":90},[2194],{"nctId":2169,"briefTitle":2170,"status":98,"phases":2195,"primaryCompletion":2172,"completion":2172,"start":2173,"enrollment":2174,"conditions":2196,"interventions":2197},[79],[173,175,176],[2160,2177,2178,2179],{"trials":2199,"activeCount":90},[],{"trials":2201,"activeCount":90},[],{"trials":2203,"activeCount":90},[],{"intervention":2178,"totalTrials":139,"cells":2205},{"EARLY_PHASE1":2206,"PHASE1":2208,"PHASE2":2210,"PHASE3":2216,"PHASE4":2218,"NA":2220},{"trials":2207,"activeCount":90},[],{"trials":2209,"activeCount":90},[],{"trials":2211,"activeCount":90},[2212],{"nctId":2169,"briefTitle":2170,"status":98,"phases":2213,"primaryCompletion":2172,"completion":2172,"start":2173,"enrollment":2174,"conditions":2214,"interventions":2215},[79],[173,175,176],[2160,2177,2178,2179],{"trials":2217,"activeCount":90},[],{"trials":2219,"activeCount":90},[],{"trials":2221,"activeCount":90},[],{"intervention":2179,"totalTrials":139,"cells":2223},{"EARLY_PHASE1":2224,"PHASE1":2226,"PHASE2":2228,"PHASE3":2234,"PHASE4":2236,"NA":2238},{"trials":2225,"activeCount":90},[],{"trials":2227,"activeCount":90},[],{"trials":2229,"activeCount":90},[2230],{"nctId":2169,"briefTitle":2170,"status":98,"phases":2231,"primaryCompletion":2172,"completion":2172,"start":2173,"enrollment":2174,"conditions":2232,"interventions":2233},[79],[173,175,176],[2160,2177,2178,2179],{"trials":2235,"activeCount":90},[],{"trials":2237,"activeCount":90},[],{"trials":2239,"activeCount":90},[],{"intervention":2241,"totalTrials":139,"cells":2242},"becatecarin",{"EARLY_PHASE1":2243,"PHASE1":2245,"PHASE2":2247,"PHASE3":2257,"PHASE4":2259,"NA":2261},{"trials":2244,"activeCount":90},[],{"trials":2246,"activeCount":90},[],{"trials":2248,"activeCount":90},[2249],{"nctId":2250,"briefTitle":2251,"status":98,"phases":2252,"primaryCompletion":2253,"completion":2253,"start":2254,"conditions":2255,"interventions":2256},"NCT00005027","Rebeccamycin Analog in Treating Patients With Advanced Kidney Cancer",[79],"2005-03","2000-06",[769],[2241],{"trials":2258,"activeCount":90},[],{"trials":2260,"activeCount":90},[],{"trials":2262,"activeCount":90},[],{"intervention":1275,"totalTrials":139,"cells":2264},{"EARLY_PHASE1":2265,"PHASE1":2267,"PHASE2":2269,"PHASE3":2275,"PHASE4":2277,"NA":2279},{"trials":2266,"activeCount":90},[],{"trials":2268,"activeCount":90},[],{"trials":2270,"activeCount":90},[2271],{"nctId":1268,"briefTitle":1269,"status":98,"phases":2272,"primaryCompletion":1271,"completion":1271,"start":1272,"enrollment":171,"conditions":2273,"interventions":2274},[79],[173,174,175,176],[1275,1276,1253,1254,1239],{"trials":2276,"activeCount":90},[],{"trials":2278,"activeCount":90},[],{"trials":2280,"activeCount":90},[],{"intervention":1276,"totalTrials":139,"cells":2282},{"EARLY_PHASE1":2283,"PHASE1":2285,"PHASE2":2287,"PHASE3":2293,"PHASE4":2295,"NA":2297},{"trials":2284,"activeCount":90},[],{"trials":2286,"activeCount":90},[],{"trials":2288,"activeCount":90},[2289],{"nctId":1268,"briefTitle":1269,"status":98,"phases":2290,"primaryCompletion":1271,"completion":1271,"start":1272,"enrollment":171,"conditions":2291,"interventions":2292},[79],[173,174,175,176],[1275,1276,1253,1254,1239],{"trials":2294,"activeCount":90},[],{"trials":2296,"activeCount":90},[],{"trials":2298,"activeCount":90},[],{"intervention":2300,"totalTrials":139,"cells":2301},"Telotristat Etiprate",{"EARLY_PHASE1":2302,"PHASE1":2304,"PHASE2":2306,"PHASE3":2318,"PHASE4":2320,"NA":2322},{"trials":2303,"activeCount":90},[],{"trials":2305,"activeCount":90},[],{"trials":2307,"activeCount":90},[2308],{"nctId":2309,"briefTitle":2310,"status":98,"phases":2311,"primaryCompletion":2312,"completion":2312,"start":2313,"enrollment":86,"conditions":2314,"interventions":2317},"NCT03453489","AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm",[79],"2020-10-15","2018-06-20",[2315,2316],"Carcinoid Syndrome","Metastatic Nonfunctional Well Differentiated Neuroendocrine Neoplasm",[2300],{"trials":2319,"activeCount":90},[],{"trials":2321,"activeCount":90},[],{"trials":2323,"activeCount":90},[],{"intervention":2325,"totalTrials":139,"cells":2326},"EGFRBi-Armed Autologous T Cells",{"EARLY_PHASE1":2327,"PHASE1":2329,"PHASE2":2331,"PHASE3":2344,"PHASE4":2346,"NA":2348},{"trials":2328,"activeCount":90},[],{"trials":2330,"activeCount":90},[],{"trials":2332,"activeCount":90},[2333],{"nctId":2334,"briefTitle":2335,"status":736,"phases":2336,"primaryCompletion":2337,"start":2338,"enrollment":90,"conditions":2339,"interventions":2343},"NCT02521090","EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma",[78,79],"2016-03","2015-08",[2340,2341,2342],"Adult Brain Glioblastoma","Adult Gliosarcoma","Recurrent Brain Neoplasm",[2325],{"trials":2345,"activeCount":90},[],{"trials":2347,"activeCount":90},[],{"trials":2349,"activeCount":90},[],{"intervention":2351,"totalTrials":139,"cells":2352},"Tacrolimus and Thymoglobulin",{"EARLY_PHASE1":2353,"PHASE1":2355,"PHASE2":2357,"PHASE3":2369,"PHASE4":2371,"NA":2373},{"trials":2354,"activeCount":90},[],{"trials":2356,"activeCount":90},[],{"trials":2358,"activeCount":90},[2359],{"nctId":2360,"briefTitle":2361,"status":98,"phases":2362,"primaryCompletion":2363,"completion":2363,"start":2364,"enrollment":2365,"conditions":2366,"interventions":2368},"NCT01246206","Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT",[79],"2013-10","2010-11",21,[2367],"Hematological Malignancies",[2351],{"trials":2370,"activeCount":90},[],{"trials":2372,"activeCount":90},[],{"trials":2374,"activeCount":90},[],{"intervention":546,"totalTrials":139,"cells":2376},{"EARLY_PHASE1":2377,"PHASE1":2379,"PHASE2":2381,"PHASE3":2387,"PHASE4":2389,"NA":2391},{"trials":2378,"activeCount":90},[],{"trials":2380,"activeCount":90},[],{"trials":2382,"activeCount":90},[2383],{"nctId":535,"briefTitle":536,"status":98,"phases":2384,"primaryCompletion":538,"completion":539,"start":540,"enrollment":541,"conditions":2385,"interventions":2386},[79],[29,23],[530,531,237,238,239,240,544,545,546,547],{"trials":2388,"activeCount":90},[],{"trials":2390,"activeCount":90},[],{"trials":2392,"activeCount":90},[],{"intervention":547,"totalTrials":139,"cells":2394},{"EARLY_PHASE1":2395,"PHASE1":2397,"PHASE2":2399,"PHASE3":2405,"PHASE4":2407,"NA":2409},{"trials":2396,"activeCount":90},[],{"trials":2398,"activeCount":90},[],{"trials":2400,"activeCount":90},[2401],{"nctId":535,"briefTitle":536,"status":98,"phases":2402,"primaryCompletion":538,"completion":539,"start":540,"enrollment":541,"conditions":2403,"interventions":2404},[79],[29,23],[530,531,237,238,239,240,544,545,546,547],{"trials":2406,"activeCount":90},[],{"trials":2408,"activeCount":90},[],{"trials":2410,"activeCount":90},[],{"intervention":2412,"totalTrials":139,"cells":2413},"B-Dim",{"EARLY_PHASE1":2414,"PHASE1":2416,"PHASE2":2418,"PHASE3":2428,"PHASE4":2430,"NA":2432},{"trials":2415,"activeCount":90},[],{"trials":2417,"activeCount":90},[],{"trials":2419,"activeCount":90},[2420],{"nctId":2421,"briefTitle":2422,"status":98,"phases":2423,"primaryCompletion":229,"completion":229,"start":2424,"enrollment":2425,"conditions":2426,"interventions":2427},"NCT00888654","Diindolylmethane in Treating Patients With Stage I or Stage II Prostate Cancer Undergoing Radical Prostatectomy",[79],"2009-08",41,[20],[2412],{"trials":2429,"activeCount":90},[],{"trials":2431,"activeCount":90},[],{"trials":2433,"activeCount":90},[],{"intervention":799,"totalTrials":139,"cells":2435},{"EARLY_PHASE1":2436,"PHASE1":2438,"PHASE2":2440,"PHASE3":2446,"PHASE4":2448,"NA":2450},{"trials":2437,"activeCount":90},[],{"trials":2439,"activeCount":90},[],{"trials":2441,"activeCount":90},[2442],{"nctId":789,"briefTitle":790,"status":98,"phases":2443,"primaryCompletion":792,"completion":792,"start":793,"enrollment":9,"conditions":2444,"interventions":2445},[78,79],[114,795,796,797],[731,799,800,801,802,803,804,805,732],{"trials":2447,"activeCount":90},[],{"trials":2449,"activeCount":90},[],{"trials":2451,"activeCount":90},[],{"intervention":805,"totalTrials":139,"cells":2453},{"EARLY_PHASE1":2454,"PHASE1":2456,"PHASE2":2458,"PHASE3":2464,"PHASE4":2466,"NA":2468},{"trials":2455,"activeCount":90},[],{"trials":2457,"activeCount":90},[],{"trials":2459,"activeCount":90},[2460],{"nctId":789,"briefTitle":790,"status":98,"phases":2461,"primaryCompletion":792,"completion":792,"start":793,"enrollment":9,"conditions":2462,"interventions":2463},[78,79],[114,795,796,797],[731,799,800,801,802,803,804,805,732],{"trials":2465,"activeCount":90},[],{"trials":2467,"activeCount":90},[],{"trials":2469,"activeCount":90},[],{"intervention":138,"totalTrials":139,"cells":2471},{"EARLY_PHASE1":2472,"PHASE1":2474,"PHASE2":2476,"PHASE3":2482,"PHASE4":2484,"NA":2486},{"trials":2473,"activeCount":90},[],{"trials":2475,"activeCount":90},[],{"trials":2477,"activeCount":90},[2478],{"nctId":128,"briefTitle":129,"status":98,"phases":2479,"primaryCompletion":131,"completion":131,"start":132,"enrollment":133,"conditions":2480,"interventions":2481},[79],[135],[137,85,138],{"trials":2483,"activeCount":90},[],{"trials":2485,"activeCount":90},[],{"trials":2487,"activeCount":90},[],{"intervention":2489,"totalTrials":139,"cells":2490},"gefitinib",{"EARLY_PHASE1":2491,"PHASE1":2493,"PHASE2":2495,"PHASE3":2504,"PHASE4":2506,"NA":2508},{"trials":2492,"activeCount":90},[],{"trials":2494,"activeCount":90},[],{"trials":2496,"activeCount":90},[2497],{"nctId":2498,"briefTitle":2499,"status":736,"phases":2500,"enrollment":90,"conditions":2501,"interventions":2503},"NCT00268255","Gefitinib and Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer",[78,79],[2502],"Non-small Cell Lung Cancer",[2489],{"trials":2505,"activeCount":90},[],{"trials":2507,"activeCount":90},[],{"trials":2509,"activeCount":90},[],{"intervention":556,"totalTrials":139,"cells":2511},{"EARLY_PHASE1":2512,"PHASE1":2514,"PHASE2":2516,"PHASE3":2522,"PHASE4":2524,"NA":2526},{"trials":2513,"activeCount":90},[],{"trials":2515,"activeCount":90},[],{"trials":2517,"activeCount":90},[2518],{"nctId":549,"briefTitle":550,"status":98,"phases":2519,"primaryCompletion":539,"completion":539,"start":552,"enrollment":553,"conditions":2520,"interventions":2521},[79],[26,33],[236,238,556,239,545],{"trials":2523,"activeCount":90},[],{"trials":2525,"activeCount":90},[],{"trials":2527,"activeCount":90},[],{"intervention":2529,"totalTrials":139,"cells":2530},"zileuton",{"EARLY_PHASE1":2531,"PHASE1":2533,"PHASE2":2535,"PHASE3":2544,"PHASE4":2546,"NA":2548},{"trials":2532,"activeCount":90},[],{"trials":2534,"activeCount":90},[],{"trials":2536,"activeCount":90},[2537],{"nctId":2538,"briefTitle":2539,"status":98,"phases":2540,"primaryCompletion":2541,"completion":158,"start":689,"enrollment":1062,"conditions":2542,"interventions":2543},"NCT00056004","Zileuton in Preventing Lung Cancer in Patients With Bronchial Dysplasia",[79],"2006-09",[105,15],[2529],{"trials":2545,"activeCount":90},[],{"trials":2547,"activeCount":90},[],{"trials":2549,"activeCount":90},[],{"intervention":190,"totalTrials":139,"cells":2551},{"EARLY_PHASE1":2552,"PHASE1":2554,"PHASE2":2556,"PHASE3":2562,"PHASE4":2564,"NA":2566},{"trials":2553,"activeCount":90},[],{"trials":2555,"activeCount":90},[],{"trials":2557,"activeCount":90},[2558],{"nctId":181,"briefTitle":182,"status":98,"phases":2559,"primaryCompletion":184,"completion":184,"start":185,"enrollment":186,"conditions":2560,"interventions":2561},[79],[20],[189,190,179],{"trials":2563,"activeCount":90},[],{"trials":2565,"activeCount":90},[],{"trials":2567,"activeCount":90},[],{"intervention":2569,"totalTrials":9,"cells":2570},"Dasatinib",{"EARLY_PHASE1":2571,"PHASE1":2573,"PHASE2":2597,"PHASE3":2599,"PHASE4":2601,"NA":2603},{"trials":2572,"activeCount":90},[],{"trials":2574,"activeCount":90},[2575,2588],{"nctId":2576,"briefTitle":2577,"status":247,"phases":2578,"primaryCompletion":2579,"completion":2579,"start":2580,"enrollment":901,"conditions":2581,"interventions":2587},"NCT01643603","Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies",[78],"2018-10-09","2012-05",[2582,2583,2584,374,2585,2586],"Non-Hodgkin's Lymphoma","Hodgkin's Lymphoma","Myeloid Leukemia","Myelodysplastic Syndrome","Lymphoid Leukemia",[2569],{"nctId":2589,"briefTitle":2590,"status":247,"phases":2591,"primaryCompletion":2579,"completion":2579,"start":2592,"enrollment":34,"conditions":2593,"interventions":2596},"NCT01609816","Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma",[78],"2015-02-12",[2582,2594,2595,2583,374],"Multiple","Mycosis Fungoides",[2569],{"trials":2598,"activeCount":90},[],{"trials":2600,"activeCount":90},[],{"trials":2602,"activeCount":90},[],{"trials":2604,"activeCount":90},[],{"intervention":2606,"totalTrials":9,"cells":2607},"anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells",{"EARLY_PHASE1":2608,"PHASE1":2610,"PHASE2":2625,"PHASE3":2627,"PHASE4":2629,"NA":2631},{"trials":2609,"activeCount":90},[],{"trials":2611,"activeCount":90},[2612,2619],{"nctId":2613,"briefTitle":2614,"status":736,"phases":2615,"primaryCompletion":2616,"completion":2616,"start":1166,"enrollment":90,"conditions":2617,"interventions":2618},"NCT00521261","Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",[78],"2008-07",[29],[2606],{"nctId":2620,"briefTitle":2621,"status":98,"phases":2622,"primaryCompletion":170,"completion":726,"start":121,"enrollment":24,"conditions":2623,"interventions":2624},"NCT00938626","Treated T Cells Followed by a Stem Cell Transplant in Treating Patients With Multiple Myeloma",[78],[23],[2606],{"trials":2626,"activeCount":90},[],{"trials":2628,"activeCount":90},[],{"trials":2630,"activeCount":90},[],{"trials":2632,"activeCount":90},[],{"intervention":1403,"totalTrials":139,"cells":2634},{"EARLY_PHASE1":2635,"PHASE1":2637,"PHASE2":2643,"PHASE3":2645,"PHASE4":2647,"NA":2649},{"trials":2636,"activeCount":90},[],{"trials":2638,"activeCount":90},[2639],{"nctId":1396,"briefTitle":1397,"status":98,"phases":2640,"primaryCompletion":1399,"completion":1399,"start":1400,"enrollment":901,"conditions":2641,"interventions":2642},[78],[23],[1403,1080,1081,1389,1404],{"trials":2644,"activeCount":90},[],{"trials":2646,"activeCount":90},[],{"trials":2648,"activeCount":90},[],{"trials":2650,"activeCount":90},[],{"intervention":1404,"totalTrials":139,"cells":2652},{"EARLY_PHASE1":2653,"PHASE1":2655,"PHASE2":2661,"PHASE3":2663,"PHASE4":2665,"NA":2667},{"trials":2654,"activeCount":90},[],{"trials":2656,"activeCount":90},[2657],{"nctId":1396,"briefTitle":1397,"status":98,"phases":2658,"primaryCompletion":1399,"completion":1399,"start":1400,"enrollment":901,"conditions":2659,"interventions":2660},[78],[23],[1403,1080,1081,1389,1404],{"trials":2662,"activeCount":90},[],{"trials":2664,"activeCount":90},[],{"trials":2666,"activeCount":90},[],{"trials":2668,"activeCount":90},[],{"intervention":2670,"totalTrials":139,"cells":2671},"Denileukin Diftitox",{"EARLY_PHASE1":2672,"PHASE1":2674,"PHASE2":2683,"PHASE3":2685,"PHASE4":2687,"NA":2689},{"trials":2673,"activeCount":90},[],{"trials":2675,"activeCount":90},[2676],{"nctId":2677,"briefTitle":2678,"status":247,"phases":2679,"primaryCompletion":2680,"completion":249,"start":2364,"enrollment":9,"conditions":2681,"interventions":2682},"NCT01251952","Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous Transplantation",[78],"2011-07",[374],[2670],{"trials":2684,"activeCount":90},[],{"trials":2686,"activeCount":90},[],{"trials":2688,"activeCount":90},[],{"trials":2690,"activeCount":90},[],{"intervention":2692,"totalTrials":139,"cells":2693},"Temozolomide",{"EARLY_PHASE1":2694,"PHASE1":2696,"PHASE2":2709,"PHASE3":2711,"PHASE4":2713,"NA":2715},{"trials":2695,"activeCount":90},[],{"trials":2697,"activeCount":90},[2698],{"nctId":2699,"briefTitle":2700,"status":247,"phases":2701,"primaryCompletion":2702,"completion":2702,"start":2703,"enrollment":9,"conditions":2704,"interventions":2707},"NCT04397679","Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly Diagnosed Glioblastoma",[78],"2024-05-14","2021-08-12",[2705,2706],"Glioblastoma","Gliosarcoma",[2692,2708],"Chloroquine",{"trials":2710,"activeCount":90},[],{"trials":2712,"activeCount":90},[],{"trials":2714,"activeCount":90},[],{"trials":2716,"activeCount":90},[],{"intervention":2708,"totalTrials":139,"cells":2718},{"EARLY_PHASE1":2719,"PHASE1":2721,"PHASE2":2727,"PHASE3":2729,"PHASE4":2731,"NA":2733},{"trials":2720,"activeCount":90},[],{"trials":2722,"activeCount":90},[2723],{"nctId":2699,"briefTitle":2700,"status":247,"phases":2724,"primaryCompletion":2702,"completion":2702,"start":2703,"enrollment":9,"conditions":2725,"interventions":2726},[78],[2705,2706],[2692,2708],{"trials":2728,"activeCount":90},[],{"trials":2730,"activeCount":90},[],{"trials":2732,"activeCount":90},[],{"trials":2734,"activeCount":90},[],{"intervention":2736,"totalTrials":139,"cells":2737},"KRN5500",{"EARLY_PHASE1":2738,"PHASE1":2740,"PHASE2":2751,"PHASE3":2753,"PHASE4":2755,"NA":2757},{"trials":2739,"activeCount":90},[],{"trials":2741,"activeCount":90},[2742],{"nctId":2743,"briefTitle":2744,"status":98,"phases":2745,"primaryCompletion":2746,"completion":2747,"start":2748,"enrollment":1167,"conditions":2749,"interventions":2750},"NCT00002923","KRN5500 in Treating Patients With Metastatic Solid Tumors",[78],"2000-01","2000-10","1997-05",[31],[2736],{"trials":2752,"activeCount":90},[],{"trials":2754,"activeCount":90},[],{"trials":2756,"activeCount":90},[],{"trials":2758,"activeCount":90},[],{"intervention":2760,"totalTrials":139,"cells":2761},"BR-DIM",{"EARLY_PHASE1":2762,"PHASE1":2764,"PHASE2":2773,"PHASE3":2775,"PHASE4":2777,"NA":2779},{"trials":2763,"activeCount":90},[],{"trials":2765,"activeCount":90},[2766],{"nctId":2767,"briefTitle":2768,"status":98,"phases":2769,"primaryCompletion":725,"completion":725,"start":2770,"enrollment":24,"conditions":2771,"interventions":2772},"NCT00305747","Diindolylmethane in Treating Patients With Nonmetastatic Prostate Cancer That Has Not Responded To Previous Hormone Therapy",[78],"2005-08",[20],[2760],{"trials":2774,"activeCount":90},[],{"trials":2776,"activeCount":90},[],{"trials":2778,"activeCount":90},[],{"trials":2780,"activeCount":90},[],{"intervention":2782,"totalTrials":139,"cells":2783},"riluzole",{"EARLY_PHASE1":2784,"PHASE1":2786,"PHASE2":2797,"PHASE3":2799,"PHASE4":2801,"NA":2803},{"trials":2785,"activeCount":90},[],{"trials":2787,"activeCount":90},[2788],{"nctId":2789,"briefTitle":2790,"status":736,"phases":2791,"primaryCompletion":2792,"completion":2792,"start":2793,"enrollment":90,"conditions":2794,"interventions":2795},"NCT00903214","Riluzole in Women With Stage I, Stage II, or Stage IIIA Breast Cancer",[78],"2011-06","2009-05",[18],[2782,2796],"polymorphism analysis",{"trials":2798,"activeCount":90},[],{"trials":2800,"activeCount":90},[],{"trials":2802,"activeCount":90},[],{"trials":2804,"activeCount":90},[],{"intervention":2796,"totalTrials":139,"cells":2806},{"EARLY_PHASE1":2807,"PHASE1":2809,"PHASE2":2815,"PHASE3":2817,"PHASE4":2819,"NA":2821},{"trials":2808,"activeCount":90},[],{"trials":2810,"activeCount":90},[2811],{"nctId":2789,"briefTitle":2790,"status":736,"phases":2812,"primaryCompletion":2792,"completion":2792,"start":2793,"enrollment":90,"conditions":2813,"interventions":2814},[78],[18],[2782,2796],{"trials":2816,"activeCount":90},[],{"trials":2818,"activeCount":90},[],{"trials":2820,"activeCount":90},[],{"trials":2822,"activeCount":90},[],{"intervention":1252,"totalTrials":139,"cells":2824},{"EARLY_PHASE1":2825,"PHASE1":2827,"PHASE2":2833,"PHASE3":2835,"PHASE4":2837,"NA":2839},{"trials":2826,"activeCount":90},[],{"trials":2828,"activeCount":90},[2829],{"nctId":1246,"briefTitle":1247,"status":736,"phases":2830,"primaryCompletion":1249,"completion":1249,"start":580,"enrollment":90,"conditions":2831,"interventions":2832},[78],[699],[1252,1253,1239,1254],{"trials":2834,"activeCount":90},[],{"trials":2836,"activeCount":90},[],{"trials":2838,"activeCount":90},[],{"trials":2840,"activeCount":90},[],{"intervention":2842,"totalTrials":139,"cells":2843},"alvocidib",{"EARLY_PHASE1":2844,"PHASE1":2846,"PHASE2":2856,"PHASE3":2858,"PHASE4":2860,"NA":2862},{"trials":2845,"activeCount":90},[],{"trials":2847,"activeCount":90},[2848],{"nctId":2849,"briefTitle":2850,"status":98,"phases":2851,"primaryCompletion":2852,"completion":1411,"start":2853,"conditions":2854,"interventions":2855},"NCT00016185","Flavopiridol and Docetaxel in Treating Patients With Advanced Solid Tumors",[78],"2003-02","2001-03",[31],[2842,107],{"trials":2857,"activeCount":90},[],{"trials":2859,"activeCount":90},[],{"trials":2861,"activeCount":90},[],{"trials":2863,"activeCount":90},[],{"intervention":1295,"totalTrials":139,"cells":2865},{"EARLY_PHASE1":2866,"PHASE1":2868,"PHASE2":2874,"PHASE3":2876,"PHASE4":2878,"NA":2880},{"trials":2867,"activeCount":90},[],{"trials":2869,"activeCount":90},[2870],{"nctId":1290,"briefTitle":1291,"status":98,"phases":2871,"primaryCompletion":836,"completion":836,"start":658,"enrollment":103,"conditions":2872,"interventions":2873},[78],[31],[652,544,1295],{"trials":2875,"activeCount":90},[],{"trials":2877,"activeCount":90},[],{"trials":2879,"activeCount":90},[],{"trials":2881,"activeCount":90},[],{"intervention":2883,"totalTrials":139,"cells":2884},"R(+)XK469",{"EARLY_PHASE1":2885,"PHASE1":2887,"PHASE2":2896,"PHASE3":2898,"PHASE4":2900,"NA":2902},{"trials":2886,"activeCount":90},[],{"trials":2888,"activeCount":90},[2889],{"nctId":2890,"briefTitle":2891,"status":98,"phases":2892,"primaryCompletion":648,"completion":648,"start":1193,"enrollment":2893,"conditions":2894,"interventions":2895},"NCT00028548","XK469 in Treating Patients With Advanced Solid Tumors",[78],22,[31],[2883],{"trials":2897,"activeCount":90},[],{"trials":2899,"activeCount":90},[],{"trials":2901,"activeCount":90},[],{"trials":2903,"activeCount":90},[],{"intervention":2905,"totalTrials":139,"cells":2906},"Chemotherapy - Squamous Cell Histologies",{"EARLY_PHASE1":2907,"PHASE1":2909,"PHASE2":2920,"PHASE3":2922,"PHASE4":2924,"NA":2926},{"trials":2908,"activeCount":90},[],{"trials":2910,"activeCount":90},[2911],{"nctId":2912,"briefTitle":2913,"status":736,"phases":2914,"primaryCompletion":2915,"completion":2915,"start":2916,"enrollment":90,"conditions":2917,"interventions":2918},"NCT01416961","Integration of Neutron Therapy in the Treatment Plan for Stage III Non-Small Cell Lung Cancer (NSCLC)",[78],"2011-12","2011-08",[15],[2905,2919],"Chemotherapy - NSCLC other than squamous cell",{"trials":2921,"activeCount":90},[],{"trials":2923,"activeCount":90},[],{"trials":2925,"activeCount":90},[],{"trials":2927,"activeCount":90},[],{"intervention":2919,"totalTrials":139,"cells":2929},{"EARLY_PHASE1":2930,"PHASE1":2932,"PHASE2":2938,"PHASE3":2940,"PHASE4":2942,"NA":2944},{"trials":2931,"activeCount":90},[],{"trials":2933,"activeCount":90},[2934],{"nctId":2912,"briefTitle":2913,"status":736,"phases":2935,"primaryCompletion":2915,"completion":2915,"start":2916,"enrollment":90,"conditions":2936,"interventions":2937},[78],[15],[2905,2919],{"trials":2939,"activeCount":90},[],{"trials":2941,"activeCount":90},[],{"trials":2943,"activeCount":90},[],{"trials":2945,"activeCount":90},[],{"intervention":1066,"totalTrials":139,"cells":2947},{"EARLY_PHASE1":2948,"PHASE1":2950,"PHASE2":2956,"PHASE3":2958,"PHASE4":2960,"NA":2962},{"trials":2949,"activeCount":90},[],{"trials":2951,"activeCount":90},[2952],{"nctId":1058,"briefTitle":1059,"status":98,"phases":2953,"primaryCompletion":170,"completion":954,"start":1061,"enrollment":1062,"conditions":2954,"interventions":2955},[78],[1064,374],[1066,242],{"trials":2957,"activeCount":90},[],{"trials":2959,"activeCount":90},[],{"trials":2961,"activeCount":90},[],{"trials":2963,"activeCount":90},[],{"intervention":2965,"totalTrials":139,"cells":2966},"DHEA",{"EARLY_PHASE1":2967,"PHASE1":2969,"PHASE2":2978,"PHASE3":2980,"PHASE4":2982,"NA":2984},{"trials":2968,"activeCount":90},[],{"trials":2970,"activeCount":90},[2971],{"nctId":2972,"briefTitle":2973,"status":247,"phases":2974,"primaryCompletion":766,"completion":2975,"start":185,"enrollment":139,"conditions":2976,"interventions":2977},"NCT00972023","DHEA in Treating Women Undergoing Surgery for Stage I, Stage II, or Stage III Breast Cancer",[78],"2010-08-22",[18],[2965],{"trials":2979,"activeCount":90},[],{"trials":2981,"activeCount":90},[],{"trials":2983,"activeCount":90},[],{"trials":2985,"activeCount":90},[],{"intervention":2987,"totalTrials":139,"cells":2988},"Antiandrogen Therapy",{"EARLY_PHASE1":2989,"PHASE1":2991,"PHASE2":3004,"PHASE3":3006,"PHASE4":3008,"NA":3010},{"trials":2990,"activeCount":90},[],{"trials":2992,"activeCount":90},[2993],{"nctId":2994,"briefTitle":2995,"status":98,"phases":2996,"primaryCompletion":2997,"completion":2997,"start":739,"enrollment":34,"conditions":2998,"interventions":3002},"NCT02472275","PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer",[78],"2019-08-05",[2999,3000,3001],"Stage I Prostate Adenocarcinoma","Stage II Prostate Adenocarcinoma","Stage III Prostate Adenocarcinoma",[2987,3003],"Multitargeted Tyrosine Kinase Inhibitor PLX3397",{"trials":3005,"activeCount":90},[],{"trials":3007,"activeCount":90},[],{"trials":3009,"activeCount":90},[],{"trials":3011,"activeCount":90},[],{"intervention":3003,"totalTrials":139,"cells":3013},{"EARLY_PHASE1":3014,"PHASE1":3016,"PHASE2":3022,"PHASE3":3024,"PHASE4":3026,"NA":3028},{"trials":3015,"activeCount":90},[],{"trials":3017,"activeCount":90},[3018],{"nctId":2994,"briefTitle":2995,"status":98,"phases":3019,"primaryCompletion":2997,"completion":2997,"start":739,"enrollment":34,"conditions":3020,"interventions":3021},[78],[2999,3000,3001],[2987,3003],{"trials":3023,"activeCount":90},[],{"trials":3025,"activeCount":90},[],{"trials":3027,"activeCount":90},[],{"trials":3029,"activeCount":90},[],{"intervention":3031,"totalTrials":139,"cells":3032},"monoclonal antibody anti-anb3 integrin",{"EARLY_PHASE1":3033,"PHASE1":3035,"PHASE2":3043,"PHASE3":3045,"PHASE4":3047,"NA":3049},{"trials":3034,"activeCount":90},[],{"trials":3036,"activeCount":90},[3037],{"nctId":3038,"briefTitle":3039,"status":736,"phases":3040,"start":944,"enrollment":90,"conditions":3041,"interventions":3042},"NCT00052403","Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors",[78],[31],[3031],{"trials":3044,"activeCount":90},[],{"trials":3046,"activeCount":90},[],{"trials":3048,"activeCount":90},[],{"trials":3050,"activeCount":90},[],{"intervention":3052,"totalTrials":139,"cells":3053},"pomalidomide",{"EARLY_PHASE1":3054,"PHASE1":3056,"PHASE2":3065,"PHASE3":3067,"PHASE4":3069,"NA":3071},{"trials":3055,"activeCount":90},[],{"trials":3057,"activeCount":90},[3058],{"nctId":3059,"briefTitle":3060,"status":247,"phases":3061,"primaryCompletion":3062,"completion":3062,"start":726,"enrollment":171,"conditions":3063,"interventions":3064},"NCT01728259","First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD",[78],"2018-10-31",[1078,1077],[3052,1080,1081],{"trials":3066,"activeCount":90},[],{"trials":3068,"activeCount":90},[],{"trials":3070,"activeCount":90},[],{"trials":3072,"activeCount":90},[],{"intervention":3074,"totalTrials":139,"cells":3075},"Valproic Acid",{"EARLY_PHASE1":3076,"PHASE1":3078,"PHASE2":3095,"PHASE3":3097,"PHASE4":3099,"NA":3101},{"trials":3077,"activeCount":90},[],{"trials":3079,"activeCount":90},[3080],{"nctId":3081,"briefTitle":3082,"status":98,"phases":3083,"primaryCompletion":3084,"completion":3085,"start":2338,"enrollment":3086,"conditions":3087,"interventions":3094},"NCT02520115","Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer",[78],"2018-09","2018-11",50,[3088,3089,3090,3091,3092,3093,744],"Adnexal Mass","Borderline Ovarian Epithelial Tumor","Ovarian Clear Cell Tumor","Ovarian Endometrioid Tumor","Ovarian Neoplasm","Ovarian Serous Tumor",[516,3074],{"trials":3096,"activeCount":90},[],{"trials":3098,"activeCount":90},[],{"trials":3100,"activeCount":90},[],{"trials":3102,"activeCount":90},[],{"intervention":662,"totalTrials":139,"cells":3104},{"EARLY_PHASE1":3105,"PHASE1":3107,"PHASE2":3113,"PHASE3":3115,"PHASE4":3117,"NA":3119},{"trials":3106,"activeCount":90},[],{"trials":3108,"activeCount":90},[3109],{"nctId":654,"briefTitle":655,"status":98,"phases":3110,"primaryCompletion":657,"completion":657,"start":658,"enrollment":659,"conditions":3111,"interventions":3112},[78],[26],[637,662],{"trials":3114,"activeCount":90},[],{"trials":3116,"activeCount":90},[],{"trials":3118,"activeCount":90},[],{"trials":3120,"activeCount":90},[],{"intervention":3122,"totalTrials":139,"cells":3123},"FOLFOX6",{"EARLY_PHASE1":3124,"PHASE1":3126,"PHASE2":3143,"PHASE3":3145,"PHASE4":3147,"NA":3149},{"trials":3125,"activeCount":90},[],{"trials":3127,"activeCount":90},[3128],{"nctId":3129,"briefTitle":3130,"status":98,"phases":3131,"primaryCompletion":3132,"completion":3132,"start":3133,"enrollment":16,"conditions":3134,"interventions":3141},"NCT01420874","Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)",[78],"2020-10-19","2011-08-17",[699,3135,3136,3137,3138,3139,3140,935],"Cancer of Pancreas","Pancreatic Neoplasm","Malignant Neoplasm of Large Intestine","Malignant Tumor of Colon","Colon Carcinoma","Cancer of Colon",[3122,3142],"EGFRBi armed ATC Infusions",{"trials":3144,"activeCount":90},[],{"trials":3146,"activeCount":90},[],{"trials":3148,"activeCount":90},[],{"trials":3150,"activeCount":90},[],{"intervention":3142,"totalTrials":139,"cells":3152},{"EARLY_PHASE1":3153,"PHASE1":3155,"PHASE2":3161,"PHASE3":3163,"PHASE4":3165,"NA":3167},{"trials":3154,"activeCount":90},[],{"trials":3156,"activeCount":90},[3157],{"nctId":3129,"briefTitle":3130,"status":98,"phases":3158,"primaryCompletion":3132,"completion":3132,"start":3133,"enrollment":16,"conditions":3159,"interventions":3160},[78],[699,3135,3136,3137,3138,3139,3140,935],[3122,3142],{"trials":3162,"activeCount":90},[],{"trials":3164,"activeCount":90},[],{"trials":3166,"activeCount":90},[],{"trials":3168,"activeCount":90},[],{"intervention":3170,"totalTrials":139,"cells":3171},"imatinib mesylate",{"EARLY_PHASE1":3172,"PHASE1":3174,"PHASE2":3183,"PHASE3":3185,"PHASE4":3187,"NA":3189},{"trials":3173,"activeCount":90},[],{"trials":3175,"activeCount":90},[3176],{"nctId":3177,"briefTitle":3178,"status":98,"phases":3179,"primaryCompletion":523,"completion":1183,"start":689,"conditions":3180,"interventions":3181},"NCT00066326","Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia",[78],[26],[3170,3182],"tanespimycin",{"trials":3184,"activeCount":90},[],{"trials":3186,"activeCount":90},[],{"trials":3188,"activeCount":90},[],{"trials":3190,"activeCount":90},[],{"intervention":3182,"totalTrials":139,"cells":3192},{"EARLY_PHASE1":3193,"PHASE1":3195,"PHASE2":3201,"PHASE3":3203,"PHASE4":3205,"NA":3207},{"trials":3194,"activeCount":90},[],{"trials":3196,"activeCount":90},[3197],{"nctId":3177,"briefTitle":3178,"status":98,"phases":3198,"primaryCompletion":523,"completion":1183,"start":689,"conditions":3199,"interventions":3200},[78],[26],[3170,3182],{"trials":3202,"activeCount":90},[],{"trials":3204,"activeCount":90},[],{"trials":3206,"activeCount":90},[],{"trials":3208,"activeCount":90},[],{"intervention":107,"totalTrials":27,"cells":3210},{"EARLY_PHASE1":3211,"PHASE1":3213,"PHASE2":3219,"PHASE3":3256,"PHASE4":3258,"NA":3260},{"trials":3212,"activeCount":90},[],{"trials":3214,"activeCount":90},[3215],{"nctId":2849,"briefTitle":2850,"status":98,"phases":3216,"primaryCompletion":2852,"completion":1411,"start":2853,"conditions":3217,"interventions":3218},[78],[31],[2842,107],{"trials":3220,"activeCount":90},[3221,3225,3229,3233,3237,3241,3245,3249],{"nctId":1214,"briefTitle":1215,"status":98,"phases":3222,"primaryCompletion":1217,"completion":1217,"start":932,"enrollment":112,"conditions":3223,"interventions":3224},[79],[20],[1196,107],{"nctId":96,"briefTitle":97,"status":98,"phases":3226,"primaryCompletion":100,"completion":101,"start":102,"enrollment":103,"conditions":3227,"interventions":3228},[79],[105],[107,85],{"nctId":1172,"briefTitle":1173,"status":98,"phases":3230,"primaryCompletion":1175,"completion":1176,"start":727,"enrollment":621,"conditions":3231,"interventions":3232},[79],[15],[1154,959],{"nctId":951,"briefTitle":952,"status":98,"phases":3234,"primaryCompletion":954,"completion":955,"start":657,"enrollment":956,"conditions":3235,"interventions":3236},[79],[15],[947,959,960],{"nctId":1180,"briefTitle":1181,"status":98,"phases":3238,"primaryCompletion":1183,"completion":1184,"start":727,"enrollment":1185,"conditions":3239,"interventions":3240},[79],[15],[1154,959],{"nctId":166,"briefTitle":167,"status":98,"phases":3242,"primaryCompletion":169,"completion":169,"start":170,"enrollment":171,"conditions":3243,"interventions":3244},[78,79],[173,174,175,176],[107,178,179],{"nctId":1670,"briefTitle":1671,"status":98,"phases":3246,"primaryCompletion":1673,"completion":1674,"start":523,"enrollment":1675,"conditions":3247,"interventions":3248},[79],[1677,1678],[1680,959,804],{"nctId":3250,"briefTitle":3251,"status":98,"phases":3252,"primaryCompletion":1674,"completion":1674,"start":943,"enrollment":914,"conditions":3253,"interventions":3254},"NCT00541099","Bevacizumab and Docetaxel in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer",[79],[15],[3255,107],"bevacizumab",{"trials":3257,"activeCount":90},[],{"trials":3259,"activeCount":90},[],{"trials":3261,"activeCount":90},[3262],{"nctId":3263,"briefTitle":3264,"status":247,"phases":3265,"primaryCompletion":3266,"completion":3267,"start":3268,"enrollment":86,"conditions":3269,"interventions":3271},"NCT02145078","Gene Expression Levels in Predicting Treatment Response in Patients With Stage IV Non-small Cell Lung Cancer",[82],"2015-06-18","2017-03-07","2014-06",[920,3270],"Stage IV Non-small Cell Lung Cancer",[107,925,652],{"intervention":1081,"totalTrials":34,"cells":3273},{"EARLY_PHASE1":3274,"PHASE1":3276,"PHASE2":3298,"PHASE3":3308,"PHASE4":3310,"NA":3312},{"trials":3275,"activeCount":90},[],{"trials":3277,"activeCount":90},[3278,3282,3286,3290],{"nctId":1396,"briefTitle":1397,"status":98,"phases":3279,"primaryCompletion":1399,"completion":1399,"start":1400,"enrollment":901,"conditions":3280,"interventions":3281},[78],[23],[1403,1080,1081,1389,1404],{"nctId":3059,"briefTitle":3060,"status":247,"phases":3283,"primaryCompletion":3062,"completion":3062,"start":726,"enrollment":171,"conditions":3284,"interventions":3285},[78],[1078,1077],[3052,1080,1081],{"nctId":3081,"briefTitle":3082,"status":98,"phases":3287,"primaryCompletion":3084,"completion":3085,"start":2338,"enrollment":3086,"conditions":3288,"interventions":3289},[78],[3088,3089,3090,3091,3092,3093,744],[516,3074],{"nctId":3291,"briefTitle":3292,"status":98,"phases":3293,"primaryCompletion":1224,"completion":3294,"start":1184,"enrollment":159,"conditions":3295,"interventions":3297},"NCT00906503","Fludeoxyglucose F 18-PET\u002FCT Scans in Patients Receiving Ultra Short-Term Dexamethasone For Lung Nodules",[78],"2012-04",[3296],"Pulmonary Nodule",[1081],{"trials":3299,"activeCount":90},[3300,3304],{"nctId":1070,"briefTitle":1071,"status":98,"phases":3301,"primaryCompletion":1073,"completion":1074,"start":1075,"enrollment":12,"conditions":3302,"interventions":3303},[79],[1077,1078],[1080,1081,242,1082],{"nctId":506,"briefTitle":507,"status":508,"phases":3305,"primaryCompletion":510,"completion":510,"start":511,"enrollment":512,"conditions":3306,"interventions":3307},[79],[514],[207,516,517,518],{"trials":3309,"activeCount":90},[],{"trials":3311,"activeCount":90},[],{"trials":3313,"activeCount":90},[3314,3318],{"nctId":577,"briefTitle":578,"status":98,"phases":3315,"primaryCompletion":580,"completion":581,"start":523,"enrollment":541,"conditions":3316,"interventions":3317},[82],[18,233,583,26,29,23,33,234,584,585,586,587],[589,207,516,590],{"nctId":3319,"briefTitle":3320,"status":98,"phases":3321,"primaryCompletion":3322,"completion":3322,"start":2100,"enrollment":728,"conditions":3323,"interventions":3328},"NCT02819024","Dexamethasone Effects in Patients With Refractory Non-Small Cell Lung Cancer Using FLT Positron Emission Tomography",[82],"2019-10-17",[3324,3325,3326,3327],"Recurrent Non-Small Cell Lung Carcinoma","Stage IIIA Non-Small Cell Lung Cancer","Stage IIIB Non-Small Cell Lung Cancer","Stage IV Non-Small Cell Lung Cancer",[516],{"intervention":652,"totalTrials":638,"cells":3330},{"EARLY_PHASE1":3331,"PHASE1":3333,"PHASE2":3343,"PHASE3":3367,"PHASE4":3369,"NA":3371},{"trials":3332,"activeCount":90},[],{"trials":3334,"activeCount":90},[3335,3339],{"nctId":1290,"briefTitle":1291,"status":98,"phases":3336,"primaryCompletion":836,"completion":836,"start":658,"enrollment":103,"conditions":3337,"interventions":3338},[78],[31],[652,544,1295],{"nctId":645,"briefTitle":646,"status":98,"phases":3340,"primaryCompletion":648,"completion":648,"start":649,"enrollment":103,"conditions":3341,"interventions":3342},[78],[31],[637,652],{"trials":3344,"activeCount":90},[3345,3349,3356,3363],{"nctId":929,"briefTitle":930,"status":98,"phases":3346,"primaryCompletion":670,"completion":932,"start":933,"enrollment":112,"conditions":3347,"interventions":3348},[79],[935],[533,937,652],{"nctId":3350,"briefTitle":3351,"status":247,"phases":3352,"primaryCompletion":726,"completion":2100,"start":3353,"enrollment":1675,"conditions":3354,"interventions":3355},"NCT00438204","Pemetrexed Disodium, Gemcitabine, and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer",[79],"2006-05",[15],[3255,652,925],{"nctId":3357,"briefTitle":3358,"status":98,"phases":3359,"primaryCompletion":766,"completion":766,"start":1400,"enrollment":8,"conditions":3360,"interventions":3361},"NCT00376948","Genistein, Gemcitabine, and Erlotinib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer",[79],[935],[3362,652],"erlotinib hydrochloride",{"nctId":789,"briefTitle":790,"status":98,"phases":3364,"primaryCompletion":792,"completion":792,"start":793,"enrollment":9,"conditions":3365,"interventions":3366},[78,79],[114,795,796,797],[731,799,800,801,802,803,804,805,732],{"trials":3368,"activeCount":90},[],{"trials":3370,"activeCount":90},[],{"trials":3372,"activeCount":90},[3373],{"nctId":3263,"briefTitle":3264,"status":247,"phases":3374,"primaryCompletion":3266,"completion":3267,"start":3268,"enrollment":86,"conditions":3375,"interventions":3376},[82],[920,3270],[107,925,652],{"intervention":1080,"totalTrials":728,"cells":3378},{"EARLY_PHASE1":3379,"PHASE1":3381,"PHASE2":3398,"PHASE3":3408,"PHASE4":3410,"NA":3412},{"trials":3380,"activeCount":90},[],{"trials":3382,"activeCount":90},[3383,3387,3394],{"nctId":1396,"briefTitle":1397,"status":98,"phases":3384,"primaryCompletion":1399,"completion":1399,"start":1400,"enrollment":901,"conditions":3385,"interventions":3386},[78],[23],[1403,1080,1081,1389,1404],{"nctId":3388,"briefTitle":3389,"status":98,"phases":3390,"primaryCompletion":2364,"completion":101,"start":3391,"enrollment":16,"conditions":3392,"interventions":3393},"NCT00288028","Bortezomib in Treating Patients With Multiple Myeloma Who Have Undergone an Autologous Peripheral Blood Stem Cell Transplant",[78],"2005-07",[23],[1080],{"nctId":3059,"briefTitle":3060,"status":247,"phases":3395,"primaryCompletion":3062,"completion":3062,"start":726,"enrollment":171,"conditions":3396,"interventions":3397},[78],[1078,1077],[3052,1080,1081],{"trials":3399,"activeCount":90},[3400,3404],{"nctId":1347,"briefTitle":1348,"status":247,"phases":3401,"primaryCompletion":249,"completion":249,"start":581,"enrollment":139,"conditions":3402,"interventions":3403},[79],[1351,1352,1353,1354],[258,257,256,241,236,1080],{"nctId":1070,"briefTitle":1071,"status":98,"phases":3405,"primaryCompletion":1073,"completion":1074,"start":1075,"enrollment":12,"conditions":3406,"interventions":3407},[79],[1077,1078],[1080,1081,242,1082],{"trials":3409,"activeCount":90},[],{"trials":3411,"activeCount":90},[],{"trials":3413,"activeCount":90},[3414],{"nctId":3415,"briefTitle":3416,"status":98,"phases":3417,"primaryCompletion":3418,"completion":3418,"start":2680,"enrollment":3419,"conditions":3420,"interventions":3504},"NCT02037256","Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma",[82],"2015-01-21",23,[3421,3422,3423,3424,3425,3426,3427,3428,3429,3430,3431,3432,3433,3434,3435,3436,3437,3438,3439,3440,3441,3442,3443,3444,3445,3446,3447,3448,3449,3450,3451,3452,3453,3454,3455,3456,3457,3458,3459,3460,3461,418,419,3462,3463,1351,3464,3465,3466,3467,3468,3469,3470,3471,3472,3473,3474,3475,3476,1352,3477,1353,3478,3479,3480,3481,3482,3483,3484,3485,3486,3487,3488,1354,3489,3490,3491,3492,3493,3494,3495,3496,3497,3498,3499,3500,3501,3502,3503],"Adult Grade III Lymphomatoid Granulomatosis","B-cell Chronic Lymphocytic Leukemia","Contiguous Stage II Adult Burkitt Lymphoma","Contiguous Stage II Adult Diffuse Large Cell Lymphoma","Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma","Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma","Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma","Contiguous Stage II Adult Lymphoblastic Lymphoma","Contiguous Stage II Grade 1 Follicular Lymphoma","Contiguous Stage II Grade 2 Follicular Lymphoma","Contiguous Stage II Grade 3 Follicular Lymphoma","Contiguous Stage II Mantle Cell Lymphoma","Contiguous Stage II Marginal Zone Lymphoma","Contiguous Stage II Small Lymphocytic Lymphoma","Cutaneous B-cell Non-Hodgkin Lymphoma","Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue","Intraocular Lymphoma","Nodal Marginal Zone B-cell Lymphoma","Noncontiguous Stage II Adult Burkitt Lymphoma","Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma","Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma","Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma","Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma","Noncontiguous Stage II Adult Lymphoblastic Lymphoma","Noncontiguous Stage II Grade 1 Follicular Lymphoma","Noncontiguous Stage II Grade 2 Follicular Lymphoma","Noncontiguous Stage II Grade 3 Follicular Lymphoma","Noncontiguous Stage II Mantle Cell Lymphoma","Noncontiguous Stage II Marginal Zone Lymphoma","Noncontiguous Stage II Small Lymphocytic Lymphoma","Progressive Hairy Cell Leukemia, Initial Treatment","Recurrent Adult Burkitt Lymphoma","Recurrent Adult Diffuse Large Cell Lymphoma","Recurrent Adult Diffuse Mixed Cell Lymphoma","Recurrent Adult Diffuse Small Cleaved Cell Lymphoma","Recurrent Adult Grade III Lymphomatoid Granulomatosis","Recurrent Adult Immunoblastic Large Cell Lymphoma","Recurrent Adult Lymphoblastic Lymphoma","Recurrent Grade 1 Follicular Lymphoma","Recurrent Grade 2 Follicular Lymphoma","Recurrent Grade 3 Follicular Lymphoma","Recurrent Small Lymphocytic Lymphoma","Refractory Hairy Cell Leukemia","Small Intestine Lymphoma","Splenic Marginal Zone Lymphoma","Stage I Adult Burkitt Lymphoma","Stage I Adult Diffuse Large Cell Lymphoma","Stage I Adult Diffuse Mixed Cell Lymphoma","Stage I Adult Diffuse Small Cleaved Cell Lymphoma","Stage I Adult Immunoblastic Large Cell Lymphoma","Stage I Adult Lymphoblastic Lymphoma","Stage I Grade 1 Follicular Lymphoma","Stage I Grade 2 Follicular Lymphoma","Stage I Grade 3 Follicular Lymphoma","Stage I Mantle Cell Lymphoma","Stage I Marginal Zone Lymphoma","Stage I Small Lymphocytic Lymphoma","Stage III Adult Burkitt Lymphoma","Stage III Adult Diffuse Large Cell Lymphoma","Stage III Adult Diffuse Mixed Cell Lymphoma","Stage III Adult Diffuse Small Cleaved Cell Lymphoma","Stage III Adult Immunoblastic Large Cell Lymphoma","Stage III Adult Lymphoblastic Lymphoma","Stage III Grade 1 Follicular Lymphoma","Stage III Grade 2 Follicular Lymphoma","Stage III Grade 3 Follicular Lymphoma","Stage III Mantle Cell Lymphoma","Stage III Marginal Zone Lymphoma","Stage III Small Lymphocytic Lymphoma","Stage IV Adult Burkitt Lymphoma","Stage IV Adult Diffuse Large Cell Lymphoma","Stage IV Adult Diffuse Mixed Cell Lymphoma","Stage IV Adult Diffuse Small Cleaved Cell Lymphoma","Stage IV Adult Immunoblastic Large Cell Lymphoma","Stage IV Adult Lymphoblastic Lymphoma","Stage IV Grade 1 Follicular Lymphoma","Stage IV Grade 2 Follicular Lymphoma","Stage IV Grade 3 Follicular Lymphoma","Stage IV Mantle Cell Lymphoma","Stage IV Marginal Zone Lymphoma","Stage IV Small Lymphocytic Lymphoma","Untreated Hairy Cell Leukemia","Waldenström Macroglobulinemia",[1080,530],{"intervention":3255,"totalTrials":901,"cells":3506},{"EARLY_PHASE1":3507,"PHASE1":3509,"PHASE2":3511,"PHASE3":3537,"PHASE4":3539,"NA":3541},{"trials":3508,"activeCount":90},[],{"trials":3510,"activeCount":90},[],{"trials":3512,"activeCount":90},[3513,3517,3521,3533],{"nctId":3350,"briefTitle":3351,"status":247,"phases":3514,"primaryCompletion":726,"completion":2100,"start":3353,"enrollment":1675,"conditions":3515,"interventions":3516},[79],[15],[3255,652,925],{"nctId":1670,"briefTitle":1671,"status":98,"phases":3518,"primaryCompletion":1673,"completion":1674,"start":523,"enrollment":1675,"conditions":3519,"interventions":3520},[79],[1677,1678],[1680,959,804],{"nctId":3522,"briefTitle":3523,"status":98,"phases":3524,"primaryCompletion":3525,"completion":101,"start":3526,"enrollment":11,"conditions":3527,"interventions":3532},"NCT01656304","Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone Therapy",[79],"2012-01","2007-05",[173,175,3528,3529,3530,3531],"Stage I Prostate Cancer","Stage IIA Prostate Cancer","Stage IIB Prostate Cancer","Stage III Prostate Cancer",[3255],{"nctId":3250,"briefTitle":3251,"status":98,"phases":3534,"primaryCompletion":1674,"completion":1674,"start":943,"enrollment":914,"conditions":3535,"interventions":3536},[79],[15],[3255,107],{"trials":3538,"activeCount":90},[],{"trials":3540,"activeCount":90},[],{"trials":3542,"activeCount":90},[3543],{"nctId":3544,"briefTitle":3545,"status":98,"phases":3546,"primaryCompletion":1673,"completion":1673,"start":1166,"enrollment":1523,"conditions":3547,"interventions":3548},"NCT00499694","Satraplatin and Bevacizumab in Treating Patients With Metastatic Prostate Cancer Previously Treated With Docetaxel",[82],[20],[3255,3549],"satraplatin",{"intervention":239,"totalTrials":901,"cells":3551},{"EARLY_PHASE1":3552,"PHASE1":3554,"PHASE2":3560,"PHASE3":3574,"PHASE4":3576,"NA":3578},{"trials":3553,"activeCount":90},[],{"trials":3555,"activeCount":90},[3556],{"nctId":819,"briefTitle":820,"status":98,"phases":3557,"primaryCompletion":822,"completion":726,"start":823,"enrollment":16,"conditions":3558,"interventions":3559},[78],[29],[532,237,239,240,242],{"trials":3561,"activeCount":90},[3562,3566,3570],{"nctId":226,"briefTitle":227,"status":98,"phases":3563,"primaryCompletion":229,"completion":229,"start":230,"enrollment":231,"conditions":3564,"interventions":3565},[79],[233,26,29,23,33,234],[216,236,237,238,239,240,241,242,243],{"nctId":535,"briefTitle":536,"status":98,"phases":3567,"primaryCompletion":538,"completion":539,"start":540,"enrollment":541,"conditions":3568,"interventions":3569},[79],[29,23],[530,531,237,238,239,240,544,545,546,547],{"nctId":549,"briefTitle":550,"status":98,"phases":3571,"primaryCompletion":539,"completion":539,"start":552,"enrollment":553,"conditions":3572,"interventions":3573},[79],[26,33],[236,238,556,239,545],{"trials":3575,"activeCount":90},[],{"trials":3577,"activeCount":90},[],{"trials":3579,"activeCount":90},[3580],{"nctId":3581,"briefTitle":3582,"status":3583,"phases":3584,"primaryCompletion":3585,"completion":3585,"start":3586,"conditions":3587,"interventions":3589},"NCT00423826","Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease","NO_LONGER_AVAILABLE",[],"2015-01","2007-01",[26,29,23,33,1264,3588],"Secondary Myelofibrosis",[3590,3591,3592,3593,258],"Busulfan","Cytarabine","Fludarabine phosphate","mycophenolate mofetil",{"intervention":236,"totalTrials":86,"cells":3595},{"EARLY_PHASE1":3596,"PHASE1":3598,"PHASE2":3600,"PHASE3":3614,"PHASE4":3616,"NA":3618},{"trials":3597,"activeCount":90},[],{"trials":3599,"activeCount":90},[],{"trials":3601,"activeCount":90},[3602,3606,3610],{"nctId":1347,"briefTitle":1348,"status":247,"phases":3603,"primaryCompletion":249,"completion":249,"start":581,"enrollment":139,"conditions":3604,"interventions":3605},[79],[1351,1352,1353,1354],[258,257,256,241,236,1080],{"nctId":226,"briefTitle":227,"status":98,"phases":3607,"primaryCompletion":229,"completion":229,"start":230,"enrollment":231,"conditions":3608,"interventions":3609},[79],[233,26,29,23,33,234],[216,236,237,238,239,240,241,242,243],{"nctId":549,"briefTitle":550,"status":98,"phases":3611,"primaryCompletion":539,"completion":539,"start":552,"enrollment":553,"conditions":3612,"interventions":3613},[79],[26,33],[236,238,556,239,545],{"trials":3615,"activeCount":90},[],{"trials":3617,"activeCount":90},[],{"trials":3619,"activeCount":90},[3620],{"nctId":3581,"briefTitle":3582,"status":3583,"phases":3621,"primaryCompletion":3585,"completion":3585,"start":3586,"conditions":3622,"interventions":3623},[],[26,29,23,33,1264,3588],[3590,3591,3592,3593,258],{"intervention":1082,"totalTrials":86,"cells":3625},{"EARLY_PHASE1":3626,"PHASE1":3628,"PHASE2":3630,"PHASE3":3636,"PHASE4":3638,"NA":3640},{"trials":3627,"activeCount":90},[],{"trials":3629,"activeCount":90},[],{"trials":3631,"activeCount":90},[3632],{"nctId":1070,"briefTitle":1071,"status":98,"phases":3633,"primaryCompletion":1073,"completion":1074,"start":1075,"enrollment":12,"conditions":3634,"interventions":3635},[79],[1077,1078],[1080,1081,242,1082],{"trials":3637,"activeCount":90},[],{"trials":3639,"activeCount":90},[],{"trials":3641,"activeCount":90},[3642,3649,3659],{"nctId":3643,"briefTitle":3644,"status":98,"phases":3645,"primaryCompletion":230,"completion":158,"start":3646,"enrollment":27,"conditions":3647,"interventions":3648},"NCT00897741","Gene Expression Profiles in Patients With Metastatic Pancreatic Cancer",[],"2004-12",[935],[1082],{"nctId":3650,"briefTitle":3651,"status":98,"phases":3652,"primaryCompletion":2541,"completion":943,"start":3653,"enrollment":1523,"conditions":3654,"interventions":3656},"NCT00899665","Proteases in Patients With Prostate Cancer That Has Spread to the Bone",[],"2001-07",[3655,161,33,1264,20],"Anemia",[3657,1082,3658],"fluorescence in situ hybridization","molecular diagnostic method",{"nctId":3660,"briefTitle":3661,"status":98,"phases":3662,"primaryCompletion":726,"completion":2363,"start":3586,"enrollment":3663,"conditions":3664,"interventions":3667},"NCT00897247","Biomarkers to Detect Mesothelioma Early in Patients Exposed to Asbestos or Vermiculite",[],494,[3665,3666],"Malignant Mesothelioma","Pulmonary Complications",[1082,3668,3669],"protein expression analysis","proteomic profiling",{"intervention":925,"totalTrials":86,"cells":3671},{"EARLY_PHASE1":3672,"PHASE1":3674,"PHASE2":3680,"PHASE3":3690,"PHASE4":3692,"NA":3694},{"trials":3673,"activeCount":90},[],{"trials":3675,"activeCount":90},[3676],{"nctId":908,"briefTitle":909,"status":98,"phases":3677,"primaryCompletion":911,"completion":912,"start":913,"enrollment":914,"conditions":3678,"interventions":3679},[78],[916,917,918,919,920,921,922,923],[533,240,925],{"trials":3681,"activeCount":90},[3682,3686],{"nctId":3350,"briefTitle":3351,"status":247,"phases":3683,"primaryCompletion":726,"completion":2100,"start":3353,"enrollment":1675,"conditions":3684,"interventions":3685},[79],[15],[3255,652,925],{"nctId":951,"briefTitle":952,"status":98,"phases":3687,"primaryCompletion":954,"completion":955,"start":657,"enrollment":956,"conditions":3688,"interventions":3689},[79],[15],[947,959,960],{"trials":3691,"activeCount":90},[],{"trials":3693,"activeCount":90},[],{"trials":3695,"activeCount":90},[3696],{"nctId":3263,"briefTitle":3264,"status":247,"phases":3697,"primaryCompletion":3266,"completion":3267,"start":3268,"enrollment":86,"conditions":3698,"interventions":3699},[82],[920,3270],[107,925,652],{"intervention":530,"totalTrials":86,"cells":3701},{"EARLY_PHASE1":3702,"PHASE1":3704,"PHASE2":3706,"PHASE3":3716,"PHASE4":3736,"NA":3738},{"trials":3703,"activeCount":90},[],{"trials":3705,"activeCount":90},[],{"trials":3707,"activeCount":90},[3708,3712],{"nctId":520,"briefTitle":521,"status":98,"phases":3709,"primaryCompletion":523,"completion":523,"start":524,"conditions":3710,"interventions":3711},[79],[526],[528,529,530,531,532,237,533,238,288],{"nctId":535,"briefTitle":536,"status":98,"phases":3713,"primaryCompletion":538,"completion":539,"start":540,"enrollment":541,"conditions":3714,"interventions":3715},[79],[29,23],[530,531,237,238,239,240,544,545,546,547],{"trials":3717,"activeCount":90},[3718],{"nctId":3719,"briefTitle":3720,"status":247,"phases":3721,"primaryCompletion":3722,"completion":3722,"start":3723,"enrollment":3419,"conditions":3724,"interventions":3735},"NCT01987596","Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer",[80],"2018-06","2013-08",[3725,3726,3727,3728,3729,585,3730,3731,3732,3733,3734],"Childhood Choroid Plexus Tumor","Childhood Medulloblastoma","Childhood Pineoblastoma","Childhood Soft Tissue Sarcoma","Childhood Supratentorial Primitive Neuroectodermal Tumor","Osteosarcoma","Retinoblastoma","Wilms Tumor and Other Childhood Kidney Tumors","Recurrent\u002FRefractory Childhood Hodgkin Lymphoma","Unspecified Childhood Solid Tumor, Protocol Specific",[530],{"trials":3737,"activeCount":90},[],{"trials":3739,"activeCount":90},[3740],{"nctId":3415,"briefTitle":3416,"status":98,"phases":3741,"primaryCompletion":3418,"completion":3418,"start":2680,"enrollment":3419,"conditions":3742,"interventions":3743},[82],[3421,3422,3423,3424,3425,3426,3427,3428,3429,3430,3431,3432,3433,3434,3435,3436,3437,3438,3439,3440,3441,3442,3443,3444,3445,3446,3447,3448,3449,3450,3451,3452,3453,3454,3455,3456,3457,3458,3459,3460,3461,418,419,3462,3463,1351,3464,3465,3466,3467,3468,3469,3470,3471,3472,3473,3474,3475,3476,1352,3477,1353,3478,3479,3480,3481,3482,3483,3484,3485,3486,3487,3488,1354,3489,3490,3491,3492,3493,3494,3495,3496,3497,3498,3499,3500,3501,3502,3503],[1080,530],{"intervention":258,"totalTrials":217,"cells":3745},{"EARLY_PHASE1":3746,"PHASE1":3748,"PHASE2":3750,"PHASE3":3760,"PHASE4":3762,"NA":3764},{"trials":3747,"activeCount":90},[],{"trials":3749,"activeCount":90},[],{"trials":3751,"activeCount":90},[3752,3756],{"nctId":1347,"briefTitle":1348,"status":247,"phases":3753,"primaryCompletion":249,"completion":249,"start":581,"enrollment":139,"conditions":3754,"interventions":3755},[79],[1351,1352,1353,1354],[258,257,256,241,236,1080],{"nctId":245,"briefTitle":246,"status":247,"phases":3757,"primaryCompletion":249,"completion":250,"start":251,"enrollment":86,"conditions":3758,"interventions":3759},[79],[233,253,26,29,254,23,33,234],[256,216,257,258],{"trials":3761,"activeCount":90},[],{"trials":3763,"activeCount":90},[],{"trials":3765,"activeCount":90},[3766],{"nctId":3581,"briefTitle":3582,"status":3583,"phases":3767,"primaryCompletion":3585,"completion":3585,"start":3586,"conditions":3768,"interventions":3769},[],[26,29,23,33,1264,3588],[3590,3591,3592,3593,258],{"intervention":241,"totalTrials":217,"cells":3771},{"EARLY_PHASE1":3772,"PHASE1":3774,"PHASE2":3776,"PHASE3":3786,"PHASE4":3788,"NA":3790},{"trials":3773,"activeCount":90},[],{"trials":3775,"activeCount":90},[],{"trials":3777,"activeCount":90},[3778,3782],{"nctId":1347,"briefTitle":1348,"status":247,"phases":3779,"primaryCompletion":249,"completion":249,"start":581,"enrollment":139,"conditions":3780,"interventions":3781},[79],[1351,1352,1353,1354],[258,257,256,241,236,1080],{"nctId":226,"briefTitle":227,"status":98,"phases":3783,"primaryCompletion":229,"completion":229,"start":230,"enrollment":231,"conditions":3784,"interventions":3785},[79],[233,26,29,23,33,234],[216,236,237,238,239,240,241,242,243],{"trials":3787,"activeCount":90},[],{"trials":3789,"activeCount":90},[],{"trials":3791,"activeCount":90},[3792],{"nctId":3581,"briefTitle":3582,"status":3583,"phases":3793,"primaryCompletion":3585,"completion":3585,"start":3586,"conditions":3794,"interventions":3795},[],[26,29,23,33,1264,3588],[3590,3591,3592,3593,258],{"intervention":3362,"totalTrials":9,"cells":3797},{"EARLY_PHASE1":3798,"PHASE1":3800,"PHASE2":3802,"PHASE3":3808,"PHASE4":3810,"NA":3812},{"trials":3799,"activeCount":90},[],{"trials":3801,"activeCount":90},[],{"trials":3803,"activeCount":90},[3804],{"nctId":3357,"briefTitle":3358,"status":98,"phases":3805,"primaryCompletion":766,"completion":766,"start":1400,"enrollment":8,"conditions":3806,"interventions":3807},[79],[935],[3362,652],{"trials":3809,"activeCount":90},[],{"trials":3811,"activeCount":90},[],{"trials":3813,"activeCount":90},[3814],{"nctId":3815,"briefTitle":3816,"status":247,"phases":3817,"primaryCompletion":185,"completion":3818,"start":3819,"enrollment":3820,"conditions":3821,"interventions":3822},"NCT00503841","Erlotinib in Treating Women Undergoing Surgery For Stage I, Stage II, or Stage III Breast Cancer",[82],"2010-05","2007-12",44,[18],[3362],{"intervention":3668,"totalTrials":9,"cells":3824},{"EARLY_PHASE1":3825,"PHASE1":3827,"PHASE2":3829,"PHASE3":3831,"PHASE4":3833,"NA":3835},{"trials":3826,"activeCount":90},[],{"trials":3828,"activeCount":90},[],{"trials":3830,"activeCount":90},[],{"trials":3832,"activeCount":90},[],{"trials":3834,"activeCount":90},[],{"trials":3836,"activeCount":90},[3837,3846],{"nctId":3838,"briefTitle":3839,"status":98,"phases":3840,"primaryCompletion":1262,"completion":3841,"start":3842,"enrollment":3843,"conditions":3844,"interventions":3845},"NCT00897494","Identification of Biomarkers for Early Detection of Pancreatic Cancer",[],"2011-04","2005-02",75,[935],[3668],{"nctId":3660,"briefTitle":3661,"status":98,"phases":3847,"primaryCompletion":726,"completion":2363,"start":3586,"enrollment":3663,"conditions":3848,"interventions":3849},[],[3665,3666],[1082,3668,3669],{"intervention":589,"totalTrials":139,"cells":3851},{"EARLY_PHASE1":3852,"PHASE1":3854,"PHASE2":3856,"PHASE3":3858,"PHASE4":3860,"NA":3862},{"trials":3853,"activeCount":90},[],{"trials":3855,"activeCount":90},[],{"trials":3857,"activeCount":90},[],{"trials":3859,"activeCount":90},[],{"trials":3861,"activeCount":90},[],{"trials":3863,"activeCount":90},[3864],{"nctId":577,"briefTitle":578,"status":98,"phases":3865,"primaryCompletion":580,"completion":581,"start":523,"enrollment":541,"conditions":3866,"interventions":3867},[82],[18,233,583,26,29,23,33,234,584,585,586,587],[589,207,516,590],{"intervention":590,"totalTrials":139,"cells":3869},{"EARLY_PHASE1":3870,"PHASE1":3872,"PHASE2":3874,"PHASE3":3876,"PHASE4":3878,"NA":3880},{"trials":3871,"activeCount":90},[],{"trials":3873,"activeCount":90},[],{"trials":3875,"activeCount":90},[],{"trials":3877,"activeCount":90},[],{"trials":3879,"activeCount":90},[],{"trials":3881,"activeCount":90},[3882],{"nctId":577,"briefTitle":578,"status":98,"phases":3883,"primaryCompletion":580,"completion":581,"start":523,"enrollment":541,"conditions":3884,"interventions":3885},[82],[18,233,583,26,29,23,33,234,584,585,586,587],[589,207,516,590],{"intervention":3549,"totalTrials":139,"cells":3887},{"EARLY_PHASE1":3888,"PHASE1":3890,"PHASE2":3892,"PHASE3":3894,"PHASE4":3896,"NA":3898},{"trials":3889,"activeCount":90},[],{"trials":3891,"activeCount":90},[],{"trials":3893,"activeCount":90},[],{"trials":3895,"activeCount":90},[],{"trials":3897,"activeCount":90},[],{"trials":3899,"activeCount":90},[3900],{"nctId":3544,"briefTitle":3545,"status":98,"phases":3901,"primaryCompletion":1673,"completion":1673,"start":1166,"enrollment":1523,"conditions":3902,"interventions":3903},[82],[20],[3255,3549],{"intervention":3905,"totalTrials":139,"cells":3906},"cabozantinib-s-malate",{"EARLY_PHASE1":3907,"PHASE1":3909,"PHASE2":3911,"PHASE3":3913,"PHASE4":3915,"NA":3917},{"trials":3908,"activeCount":90},[],{"trials":3910,"activeCount":90},[],{"trials":3912,"activeCount":90},[],{"trials":3914,"activeCount":90},[],{"trials":3916,"activeCount":90},[],{"trials":3918,"activeCount":90},[3919],{"nctId":3920,"briefTitle":3921,"status":98,"phases":3922,"primaryCompletion":3923,"completion":3924,"start":726,"enrollment":8,"conditions":3925,"interventions":3926},"NCT01812668","Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer",[82],"2019-01-18","2019-06-18",[173,174,175,176],[3905],{"intervention":3928,"totalTrials":139,"cells":3929},"electrophoretic mobility shift assay",{"EARLY_PHASE1":3930,"PHASE1":3932,"PHASE2":3934,"PHASE3":3936,"PHASE4":3938,"NA":3940},{"trials":3931,"activeCount":90},[],{"trials":3933,"activeCount":90},[],{"trials":3935,"activeCount":90},[],{"trials":3937,"activeCount":90},[],{"trials":3939,"activeCount":90},[],{"trials":3941,"activeCount":90},[3942],{"nctId":3943,"briefTitle":3944,"status":98,"phases":3945,"primaryCompletion":3946,"completion":3946,"start":1399,"enrollment":914,"conditions":3947,"interventions":3949},"NCT00768118","A Nutritional Supplement Capsule Containing Curcumin, Green Tea Extract, Polygonum Cuspidatum Extract, and Soybean Extract in Healthy Participants",[82],"2008-09",[3948],"Healthy, no Evidence of Disease",[3928],{"intervention":3951,"totalTrials":139,"cells":3952},"zoledronate therapy",{"EARLY_PHASE1":3953,"PHASE1":3955,"PHASE2":3957,"PHASE3":3959,"PHASE4":3961,"NA":3963},{"trials":3954,"activeCount":90},[],{"trials":3956,"activeCount":90},[],{"trials":3958,"activeCount":90},[],{"trials":3960,"activeCount":90},[],{"trials":3962,"activeCount":90},[],{"trials":3964,"activeCount":90},[3965],{"nctId":3966,"briefTitle":3967,"status":98,"phases":3968,"primaryCompletion":3723,"completion":2338,"start":725,"enrollment":914,"conditions":3969,"interventions":3970},"NCT01205646","PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer",[82],[20],[3951],{"intervention":3593,"totalTrials":139,"cells":3972},{"EARLY_PHASE1":3973,"PHASE1":3975,"PHASE2":3977,"PHASE3":3979,"PHASE4":3981,"NA":3983},{"trials":3974,"activeCount":90},[],{"trials":3976,"activeCount":90},[],{"trials":3978,"activeCount":90},[],{"trials":3980,"activeCount":90},[],{"trials":3982,"activeCount":90},[],{"trials":3984,"activeCount":90},[3985],{"nctId":3581,"briefTitle":3582,"status":3583,"phases":3986,"primaryCompletion":3585,"completion":3585,"start":3586,"conditions":3987,"interventions":3988},[],[26,29,23,33,1264,3588],[3590,3591,3592,3593,258],{"intervention":3657,"totalTrials":139,"cells":3990},{"EARLY_PHASE1":3991,"PHASE1":3993,"PHASE2":3995,"PHASE3":3997,"PHASE4":3999,"NA":4001},{"trials":3992,"activeCount":90},[],{"trials":3994,"activeCount":90},[],{"trials":3996,"activeCount":90},[],{"trials":3998,"activeCount":90},[],{"trials":4000,"activeCount":90},[],{"trials":4002,"activeCount":90},[4003],{"nctId":3650,"briefTitle":3651,"status":98,"phases":4004,"primaryCompletion":2541,"completion":943,"start":3653,"enrollment":1523,"conditions":4005,"interventions":4006},[],[3655,161,33,1264,20],[3657,1082,3658],{"intervention":3658,"totalTrials":139,"cells":4008},{"EARLY_PHASE1":4009,"PHASE1":4011,"PHASE2":4013,"PHASE3":4015,"PHASE4":4017,"NA":4019},{"trials":4010,"activeCount":90},[],{"trials":4012,"activeCount":90},[],{"trials":4014,"activeCount":90},[],{"trials":4016,"activeCount":90},[],{"trials":4018,"activeCount":90},[],{"trials":4020,"activeCount":90},[4021],{"nctId":3650,"briefTitle":3651,"status":98,"phases":4022,"primaryCompletion":2541,"completion":943,"start":3653,"enrollment":1523,"conditions":4023,"interventions":4024},[],[3655,161,33,1264,20],[3657,1082,3658],{"intervention":3669,"totalTrials":139,"cells":4026},{"EARLY_PHASE1":4027,"PHASE1":4029,"PHASE2":4031,"PHASE3":4033,"PHASE4":4035,"NA":4037},{"trials":4028,"activeCount":90},[],{"trials":4030,"activeCount":90},[],{"trials":4032,"activeCount":90},[],{"trials":4034,"activeCount":90},[],{"trials":4036,"activeCount":90},[],{"trials":4038,"activeCount":90},[4039],{"nctId":3660,"briefTitle":3661,"status":98,"phases":4040,"primaryCompletion":726,"completion":2363,"start":3586,"enrollment":3663,"conditions":4041,"interventions":4042},[],[3665,3666],[1082,3668,3669]]